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Mast cells (MCs) are thought to be key effector cells in chronic urticaria including 
cholinergic urticaria (CholU). Although the pathophysiology of CholU is not well 
understood, degranulation of mast cells upon exercise and sweating with subsequent 
release of histamine and other mediators are held to provoke the elicitation of small 
wheals, flare and often severe itch. However, as of now, only little data support this theory.  
 
Accordingly, this study aimed to better characterize the role of MCs in CholU. To this end, 
we clinically characterized patients with CholU, collected histological samples of the skin 
before and after puls-controlled provocation testing (PCE), analyzed them for skin MC 
numbers, analyzed MC activating factors like total and specific IgE, analyzed MC 
products such as tryptase, investigated the expression of MC product-related receptors 
like histamine receptors, and looked for non-IgE mediated mast cell activation pathways 
and mechanisms including acethylcholine/achethylcholine esterase dysregulation.  
 
We characterized 13 CholU patients and 13 matched healthy controls. Clinically, patients 
with CholU in our cohort had a long duration of disease and rated themselves as mostly 
moderately affected. PCE testing showed comparable onset of sweating in patients with 
CholU and healthy persons, but most of the patients with CholU had decreased sweating 
responses. Atopic predisposition was frequent in patients with CholU, and total IgE serum 
levels were elevated. Specific IgE against the skin resident fungi Malassezia was only 
seen in CholU patients and may be a marker for more prolonged courses of disease. Our 
results showed that MC numbers were increased in the skin of CholU patients compared 
to healthy controls, but we failed in detecting degranulation of MCs upon exercise 
challenge. The MC mediator tryptase did not increase in the serum upon provocation in 
CholU patients, despite often severe skin symptoms. Skin of CholU patients expressed 





In summary, the increase in skin MC numbers in CholU patients points towards a role of 
MC in the pathology of the disease, albeit the exact role remains unclear, as we failed to 
prove degranulation. It is worth nothing that differences in cutaneous histamine receptor 
expression were seen, but for meaningful conclusions, further analyses in a larger 







Mastzellen wird eine zentrale Rolle in der Pathophysiologie der chronischen Urtikaria 
einschließlich der cholinergischen Urtikaria (CholU) zugeschrieben. Obwohl die genaue 
Rolle von Mastzellen bei der CholU nicht gut verstanden ist, wird davon ausgegangen, 
dass Anstrengung und Schwitzen zu deren Degranulation führt. Mastzell-Mediatoren wie 
Histamin werden für die typischen Symptome der CholU, wie Quaddeln, Rötungen und 
oftmals starken Juckreiz verantwortlich gemacht. Obwohl die CholU eine schon lange 
bekannte Erkrankung ist, die klinisch gut charakterisiert ist, gibt es nur sehr wenige Daten 
die die Rolle von Mastzellen in der Pathogenese der CholU stützen. 
 
In dieser Studie hatten wir daher zum Ziel, die Rolle von Mastzellen bei CholU besser zu 
chrakterisieren. Von klinisch sehr gut charakterisierten Patienten wurden daher Haut- und 
Blutproben vor und nach einer Puls-kontrollierten Ergometrie (PCE) gewonnen, die 
Anzahl der Mastzellen in der Haut bestimmt, Mastzell-aktivierende Faktoren wie gesamt-
IgE und spezifisches IgE untersucht, Mastzell-Produkte wie Tryptase quantifiziert, die 
Expression von Rezeptoren für Mastzell-Produkte ermittelt und nicht-IgE vermittelte 
Mastzell-Aktivierungswege und -Mechanismen wie Acethylcholine/Achethylcholine-
Esterase Dysregulierung untersucht. 
 
In dieser Studie wurden insgesamt Proben von 13 CholU Patienten und 13 passenden 
gesunden Kontrollpersonen untersucht. Die CholU Patienten in unserer Kohorte wiesen 
einen langen Krankheitsverlauf auf und waren meist moderat von der Erkrankung 
betroffen. In der PCE wiesen Patienten mit CholU ein zeitlich ähnliches aber geringeres 
Schwitzverhalten im Vergleich zu den gesunden Kontrollen auf. CholU Patienten hatten 
mehr atopische Stigmata und erhöhte gesamt-IgE Spiegel auf. Einige Patienten wiesen 
spezifisches IgE gegen den Hautkeim Malassezia auf, das mit längerer Krankheitsdauer 
assoziiert war. Die Anzahl der Mastzellen in der Haut von CholU Patienten war signifikant 
erhöht im Vergleich zu gesunden Kontrollen, jedoch konnte wir keine Degranulation der 
Mastzellen detektieren. Im Serum der Patienten zeigte sich keine Erhöhung der Tryptase, 
trotz oft stark ausgeprägten Hautbeschwerden nach Provokationstestung. In der Haut 
von CholU Patienten zeigte sich eine niedrige Expression von Histamin H1 und H2 
Rezeptoren und eine hohe Expression der H4 Rezeptoren. H3 Rezeptorexpression 





Zusammengefasst ergab unsere Studie eine signifikante Erhöhung der Anzahl kutaner 
Mastzellen, was auf eine wichtige Rolle in der Pathophysiologie der Erkrankung hinweist, 
auch wenn die genaue Rolle weiterhin unklar bleibt. Außerdem sahen wir 
unterschiedliche Histaminrezeptorexpressionsmuster, jedoch müssen hier noch weitere 






3.1 Mast cells 
Mast cells (MCs), first described by Paul Ehrlich in 1877 1, are known to be primary 
effector cells in allergy, particularly, during the early and acute phases. Using aniline 
blue/methyl Blue staining, Ehrlich observed highly granulated cells present in the 
intestinal mucosa and named them MCs. He also found that these cells increase in 
numbers in pathological conditions involving chronic inflammation. However, the central 
role of MCs in allergy was revealed only when they were shown to release histamine 
upon immunoglobulin E (IgE)-induced cell activation, results which were published in 
1953 and 1966 2,3, nearly a century after Ehrlich's first discovery 4.  
 
MCs are found in all tissues, primarily within tissues that connect to the outside 
environment such as the intestinal tract, lungs and skin where pathogens and allergens 
are frequently encountered. MCs, together with dendritic cells (DCs), are one of the first 
responders to harmful toxins, pathogens, parasites, allergens and environmental 
antigens. They play a key role in innate immunity and adaptive immunity, and their 
malfunction can result in chronic disease, mainly allergic disease and autoimmune 
disease 5. MCs are multifunctional immune cells and the primary responders in allergic 
reactions, orchestrating strong immune responses within minutes of encountering 
allergens and other IgE-dependent or independent stimuli 5,6. 
 
Within minutes of the activation of MCs, degranulation occurs whereby MCs release 
preformed mediators, including histamine, from cytoplasmic granules 7. Histamine is the 
best known biogenic amine and was one of the first functional active MC mediators to be 
described 8,9. 
 
In the second phase, newly synthesized lipid mediators, such as prostaglandins and 
leukotrienes are released by MCs followed by a late phase release of cytokines and 
chemokines, usually several hours after activation. Importantly, not all stimuli trigger a 
full-blown response. Thus, depending on the type of stimulus involved and the type of 




The skin is the largest organ in the human body, which functions primarily as a barrier to 
the environment, thereby protecting the body from pathogens, environmental agents, hot 
or cold, stress, and water loss. In the skin, MCs are located in all vascularized tissues, 
such as the dermis and the subcutaneous layers. Yet, the distribution of MCs is not 
homogeneous. In the skin, MCs are predominantly found close to sensory nerve fibers, 
hair follicles, blood and lymphatic vessels and subcutaneous nerve plexus (Fig.1) 10,11. 
There is also a gradient of cutaneous MC numbers from the top to the bottom, with higher 
MC frequencies in the superficial layers of the skin and the lowest frequencies in the 
subcutaneous layers. Moreover, higher numbers of MCs are found at peripheral sites of 
the body like the hands, feet and face compared to the back skin or trunk. Collectively, 
these data show that the local microenvironment, i.e. tissue cells and signals, is of critical 
importance for shaping MC phenotypes. Since all tissue signals and cell populations, 
including MCs, exhibit non-homogenous distribution patterns, it suggests that MCs within 
a certain tissue are heterogeneous and show differences based on their localization within 






              Mast cell                 Blood vessels 
                     Nerve                 Lymph vessels 
   
Fig. 1  Skin localization of mast cells. 
Abbreviations: SC - Stratum Corneum, SG - Stratum Granulosum, SS - Stratum Spinosum, SB - 
Statum Basale. (Modified from Wong DJ, Chang HY., 2008-2009) 
 
Histamine and Histamine receptors 
MCs generate and release histamine during anaphylactic reactions, and pharmacological 
evidence exists to show that histamine regulates this process via specific receptors 12. 
Histamine is a multifunctionally active mast cell mediator and it is ubiquitously released 
from activated tissue MCs and blood basophils. Histamine can produce powerful 




target cells. The four histamine receptors include H1R, H2R, H3R, and H4R 13–17. 
Stimulation of H1R increases the heart rate, cardiac output, vascular permeability, 
production of nasal mucus, bronchial and intestinal smooth muscle contractions, and T 
cell, neutrophil and eosinophil chemotaxis 11,18. Stimulation of H2R increases gastric acid 
secretion, airway mucus production, and inhibits neutrophil and eosinophil influx into 
tissues 18,19. H3R have been found in the brain in a variety of neurologic disorders 20, 
expressed in the central nervous system and to a lesser extent the peripheral nervous 
system, where they act as autoreceptors in presynaptic histaminergic neurons, and also 
control histamine turnover by feedback inhibition of histamine synthesis and release 21. 
H4R is preferentially expressed on immune cells, such as eosinophils 22,23, basophils 24, 
natural killer (NK) cells, DCs, monocytes 25, T cells 26 and MCs 27–29. The H4R was 
highlighted as a promising therapeutic target in atopic dermatitis, chronic arthritis and 
asthma 27,30. The H4R has also been implicated in the regulation of other non-
hematopoietic systems 30. The functional link from the activation of individual histamine 




Urticaria is a skin disease, also known as hives. The symptoms are sudden whealing 
and/or deep swellings, associated with local redness of the skin and itching. In severe 
cases, urticaria may also burn and sting. Urticarial patches often start in various body 
areas and show a high fluctuation around the body. In most cases, urticaria lasts for 
several days (acute urticaria), disappearing without irreversible damage. In less than 5% 
of cases, symptoms continue to develop for more than six weeks (chronic urticaria) 31. 
 
It is estimated that around 20% - 25% of people are affected by urticaria in their lifetime 
32. Adults are held to be more vulnerable than children to chronic urticaria. In adults, 
females are more commonly affected than males. However, no distinct difference 
between males and females has been reported in the pediatric population. The duration 
of disease tends to be longer in females. Generally, middle-aged females  tend to suffer 





Often, acute urticaria occurs after a viral infection or from an allergic reaction to drugs or 
food. Other factors like psychological stress or exercise can exacerbate urticaria. A 
history of hay fever or asthma is an important risk factor 34.  
 
3.2.2 Categorization of urticaria 
The group consensus meeting [include EAACI (European Academy of Allergology and 
Clinical Immunology) Dermatology Section, the EU-funded network of excellence, 
GA2LEN (Global Allergy and Asthma European Network), the EDF (European 
Dermatology Forum) and UNEV (urticaria network e.V.)] gave new advice on the 
definition and diagnosis of chronic urticaria in December 2008 35. In 2017, the 
EAACI/GA2LEN/EDF/WAO guideline on urticaria was updated and revised and currently 
recommends that urticaria is classified based on its duration as acute (≤ 6 weeks) or 
chronic (> 6 weeks) 36.  
Chronic urticaria subtypes: 
   i) Chronic spontaneous urticaria:  
      Spontaneous appearance of wheals, angioedema or both > 6 weeks due to known 
(e.g. autoreactivity: the presence of MCs activating autoantibodies) or unknown causes. 
   ii) Chronic inducible urticaria:  
       Symptomatic dermographism (also called urticaria factitia or dermographic 
urticaria); cold urticaria (also called cold contact urticaria); delayed pressure urticaria (also 
called pressure urticaria); solar urticaria; heat urticaria (also called heat contact urticaria); 
vibratory angioedema; cholinergic urticaria; contact urticaria; aquagenic urticaria.  
 
Chronic spontaneous urticaria 
Recurrent urticaria, i.e. wheals, angioedema or both, for longer than 6 weeks is classified 
as chronic urticaria, either chronic spontaneous urticaria or chronic inducible urticaria. 
Inducible urticarias account for 25% of all chronic forms of urticaria and occur more 
frequently in young adults 37. 
 
Inducible urticarias 
Inducible urticaria is defined as a unique subpopulation of chronic urticaria in which 
urticaria can be induced reproducibly by different specific physical stimuli on the skin, 




mechanical triggers (friction, pressure, vibration. There are also forms of inducible 
urticaria, where symptoms are provoked by exercise (cholinergic urticaria) or water 
contact (aquagenic urticaria). 
 
Cholinergic urticaria 
Cholinergic urticaria (CholU) is a common form of urticaria, which is clinically 
characterized by pinpoint-sized wheals, large flares and severe itch. It is a subtype of 
chronic inducible urticaria, symptoms of which are evoked by sweating 38 38,39. Symptoms 
can often be induced by exercise, passive warming (environmental heat, warm baths), 
emotional stress, and in some cases, hot and spicy food 40. In the past, there were reports 
that a rise in body temperature of more than 0.7°C or an increase in the core body 
temperature is needed to provoke CholU 41,42. However, some reports have shown that 
there is no correlation between the time to wheal formation and the time to increase either 
core or mean body temperature (MBT) 38. Wheals in cholinergic urticaria are usually 
smaller (1-2 mm diameter pruritic wheals surrounded by a red flare) than those in 
spontaneous urticaria and of shorter duration. The itching, erythema and wheals normally 
subside within 30 minutes 43,44. Cholinergic urticaria induced by exercise usually occurs 
after 6 minutes of onset of exercise. Increased clinical symptoms and physical signs occur 
approximately 12 to 25 minutes later 41.  
 
3.3 Cholinergic Urticaria 
3.3.1 Epidemiology 
As described before, CholU is a frequent form of chronic inducible urticaria, where 
symptoms of wheals, flares and itch are evoked by sweating, upon environmental heat, 
warm bath, emotional distress, exercise and, in some patients, by some hot and spicy 
food 40.  
 
Since 1924, when Duke first described CholU 45, many studies 46–49 have characterized 
this disease, mainly based on clinical features. CholU can occur at any age, but young 
adults are most commonly affected. In this population, CholU affects up to 20%, but only 
0.2% of all dermatological patients present with CholU 43, indicating that most CholU 




usually lasting for several years, with a serious impact on the quality of life. Severely 
affected patients are not able to study, work or do housework 40. 
 
CholU generally has a favorable prognosis 50: Hessman reported that only 31% of 
patients had symptoms lasting longer than 10 years. Sibbald reported that the average 
duration of symptoms was estimated to be 7.5 years and ranged from 3 to 16 years 51. 
The peak incidence of young adults is between 10 to 30 years of age 44,52–54. 
 
3.3.2 Pathomechanism 
CholU forms a heterogeneous disease group, and the underlying pathomechanisms are 
not completely understood 55. Recently, Japanese studies suggested four distinct CholU 
subclasses 55,56:  
  i) CholU with poral occlusion: caused by poral occlusion, occlusion of superficial 
acrosyringium due to keratotic plugs and dilatation of sweat ducts are evident by 
histological examination. Most cases of this type have been reported in Asia; this type of 
CholU is very rarely reported in Europe. Thus, CholU due to poral occlusion may be 
related to hot and humid climates.  
  ii) CholU with hypohidrosis: CholU is sometimes accompanied by acquired generalized 
hypohidrosis (AGH), suggesting that the sweat itself is not essential for the initiation of 
CholU. In patients with AGH, the inhibited sweat production may cause the elevation of 
local acetycholine levels. Consequently, excess acetylcholine could stimulate sensory 
nerve endings to evoke pain and act on muscarinic receptors on MCs in the vicinity of 
sweat glands to cause wheals. In one case of CholU, a patient with AGH showed an 
absence of muscarinic receptor expression on MCs 57. Additionally, a recent study found 
that the expression of acetylcholine esterase (AchE) was decreased in exocrine epithelial 
cells, and acetylcholine was not completely degraded due to the lack of AchE 58. 
Consequently, acetylcholine is thought to spill over to neighboring MCs and stimulate 
them to degranulate. 
  iii) CholU with possible sweat allergy: passive transfer experiments suggest a 
pathophysiological role of IgE in physical urticaria, but clear evidence is still lacking 59. In 
CholU, there is evidence that the symptoms are induced by an allergy to components of 
human sweat. Specific IgE to sweat is present in patients with CholU, but not in normal 




released high amounts of histamine in vitro 53. In addition, recent reports suggest that 
antigens of Malassezia globosa, a skin resident fungus, may be contained in human 
sweat, which acts as an allergen to induce histamine release from mast cells and 
basophils in patients with CholU 60.  
  iv) Idiopathic CholU: Previous reports described the three major causes of CholU, 
described above however, there still remain patients with CholU who do not fit into these 
categories. CholU in these patients, CholU is categorized tentatively as idiopathic 56.  
 











i Winter Typically 
negative 
Negative Occasional Bathing, 
keratolytic 
agents 
ii Perennial Positive Negative Always Systemic steriod 
therapy 
iii    -- Positive Positive None Anti-IgE therapy 
desensitization 
iv    -- Negative Negative None Antihistamine 
drugs 
3.3.3 Signs and Symptoms 
CholU is the only form of chronic urticaria, where wheals are very small and pin point 
sized, usually surrounded by large flare reactions and often accompanied by a severe 
itch. The wheals typically appear on the upper body and usually remain for a few minutes 
up to an hour before they spontaneously disappear 61–63. 
 
3.3.4 Diagnosis 
The diagnosis of CholU is based on the patient history and provocation testing. Typical 
features of CholU, in contrast to other forms of urticaria, include small wheal size and 
short duration of the wheals. Usually patients do not display symptoms when they present 





Provocation tests for CholU are based on increasing the body temperature either 
through exercise (e.g. on a treadmill or stationary bicycle) or by using a hot bath or sauna 
35,64,65. Illig reported that a medium rise in MBT of 0.7°C was necessary to cause whealing 
64. Furthermore, the EAACI/GA2LEN/EDF/UNEV consensus panel recommendation for 
confirming the diagnosis of CholU is to achieve a rise of ≥1.0°C in core body temperature 
by a passive warming test consisting of sitting for up to 15 minutes in a bath full of water 
at 42°C 35. These tests allow the diagnosis of CholU, but not grading of disease severity. 
 
More recently, our team has developed and published a specific pulse-controlled 
ergometry (PCE) protocol for standardizing the diagnosis of CholU and to objectively 
assess disease activity. This approach also includes an assessment of the provocation 
UAS (Urticaria Activity Score), which allows a grading of the resulting symptoms. 
 
Patient-reported outcomes 
In a recent publication, our working group has introduced several patient-reported 
outcome measurements, which allow for the characterization and quantification of CholU 
symptoms. For disease activity, the CholU Activity Score (CholUAS7), and for quality of 
life, the CholU Quality of Life (CholU-Qol) Questionnaire has been developed. 
3.3.5 Mast cell-related physiopathology in CholU 
Although the underlying causes of CholU are still not completely understood, it is believed 
that the activation of MCs in the skin and their release of histamine and other 
proinflammatory mediators are the most relevant factors. Histologically, wheals and 
edema occur on the skin, and molecules released by MCs cause blood vessels to dilate 
and fluids to penetrate the skin. MCs play an important role in most patterns of urticaria 
via the release of histamine and other inflammatory mediators such as cytokines, 
chemokines and leukotrienes (Figure 2). Histamine acts on cutaneous nerve endings to 
induce characteristic pruritus. In chronic urticaria, it has been demonstrated that MC 
activation can not occur only via specific IgE-allergen interactions, but also via 
autoreactive mechanisms, like functional autoantibodies against IgE and high-affinity IgE 
receptors on MCs and basophils, which lead to cross-linking of the high-affinity IgE 





Tryptase is a serine protease that is primarily produced and stored in MCs and less 
abundantly, in blood basophils. The basal serum tryptase level in healthy individuals is 
caused by the constant release of enzymes from mature tissue MCs 66. The median 
serum tryptase level in healthy adults averages about 5 ng/ml and ranges from < 1 to 30 
ng/ml. Serum tryptase levels are less than or equal to 15 ng/ml in more than 99% of 
healthy people 67–69. Despite this, in commercially available tests, the normal range is 
usually set at < 11.4 ng/ml or even < 10 ng/ml 70. Serum tryptase levels in healthy 
individuals increase with age 68,71, and many healthy individuals have serum tryptase 








Urticaria guidelines  
The current urticaria guidelines (shown in Table 2) give treatment recommendations for 
all forms of chronic urticaria including CholU. 
 
Non-sedating H1 antihistamines, and within this group, specifically second generation 
antihistamines (sgAHs) are recommended as the first-line treatment of mild to moderate 




severe cases of urticaria, if the standard dose for refractory urticaria is ineffective, there 
is evidence that increasing the dose up to four times may control the symptoms without 
compromising the patient's safety 6,73, and this is the recommended second line treatment 
option. But there is still a large patient cohort that remains symptomatic despite this 
updosing 74. To date, there are no other licensed drugs available for the treatment of 
patients with CholU. Omalizumab, an anti-IgE monoclonal antibody, which is licensed for 
the treatment of chronic spontaneous urticaria (CSU), has also been shown to be effective 
in some case reports in CholU, but this treatment is currently not available for most 
patients.  
Table 2 Recommended treatment algorithm for chronic urticaria including CholU 
Second-generation H1 antihistamine (nsAH*) 
In case of insufficient control after 2-4 weeks or sooner if symptoms are intolerable. 
Updosing of nsAH (up to 4 times the standard dose) 
In case of insufficient control after 2-4 weeks or sooner if symptoms are intolerable. 
In addition to nsAH: omalizumab 
In case of insufficient control after 6 months or sooner if symptoms are intolerable. 
In addition to nsAH: cyclosporine 
*nsAH: non-sedating antihistamine 
 
Further treatment options: 
In earlier case reports, anticholinergic substances such as clidinium bromide 75 or 
scopolamine butylbromide 76,77 were used to relieve symptoms. In recent years, there 
have been reports of successful treatments of severely affected patients who were 
refractory to antihistamines, using methylvaleronitrile, an anticholinergic drug 78. 
Methatheliniumbromide is currently licensed in Germany for the treatment of 
hyperhidrosis and has been shown to be effective in CholU in a case report 78. 
 
3.3.7 Current problems in the treatment of CholU 
Antihistamines are the first-line treatment for CholU. These are the only licensed drugs 
for this disease, but they are often ineffective. The next treatment step (updosing) is off-
label, and only very limited publications regarding this treatment algorithm are available 
for CholU. Some drugs like omalizumab and methantheliniumbromide have been shown 





The limited available therapeutic options result from the limited understanding of the 
pathophysiology of the disease and the little known drivers of different clinical 
characteristics of patients with CholU. Currently, it is unclear whether patients show 
differences at various ages in the clinical features of CholU, duration of disease, 
comorbidities and response to treatment. 
 
The role of MCs is also not completely understood and needs to be investigated in more 
detail, it could be beneficial for this patient cohort to understand if MC-directed therapies. 
Specifically, it is not clear, if MC activation can occur via specific IgE-mediated 
mechanisms or via acethylcholine-receptor aberrations, if MC numbers are altered in 
CholU, if MCs release histamine and tryptase upon whealing in CholU, and if patients 
with CholU have aberrations in the downstream histamine pathyway (e.g. histamine-
receptor). In order to address some of these questions, the following study has been 
performed. 
 
3.4 Aim of the study 
The main goal of this project was to explore the role and relevance of MCs in the 
pathophysiology of patients with CholU compared to healthy controls. 
 
To achieve this goal we aimed to: 
 
1) clinically characterize patients with CholU and compare them to a matched, healthy 
control group. 
 
2) assess MC activating factors in CholU by: 
    A) assessing the prevalence and relevance of atopy in the two groups. 
    B) investigating possible the MC triggers, such as total and specific IgE. 
C) analyzing possible correlations between these MC triggers and clinical 
parameters.  
 
3) analyze aberrations in the MC status of the skin in patients with CholU by: 
    A) studying the difference of MC number and degranulation status between patients 




B) comparing the variations of MCs in amount and degranulation status after motion 
stimulation between the two groups. 
 
4) look for MC products (tryptase levels before and after the provocation between the two 
groups) and their correlation with clinical markers. 
5）analyze possible dysregulations of mediator-receptor interactions possibly involved in 
CholU: 
     A) histamine receptors 
     B) ACH (acetylcholine) esterase 
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4. Materials and Methods  
The appliances, chemicals, antibodies, media, buffers, kits and disposables used in this 
study are listed below. The concentrations and specific applications of the listed materials 
are specified in the corresponding method section. 
 
4.1 Appliances 
All the appliances and instruments used for this doctoral thesis are listed in table 3. 
Table 3 List of appliances employed for this study 
Appliance Model Distributor 
Caliper Series No 10-4987015-BR Bruune flexlineal, Germany 
Centrifuge Megafuge 1.0 STR Heraeus, Hanau, Germany 
Microscope Zeiss Axioplan 2  Zeiss, Germany 
Microscope Confocal DMI 6000 Leica, Germany 
Traying 
cabinet 
Hera cell Heraeus, Hanau, Germany 
PH-Meter pH-Fix 4.5-10.0 Laborbedarf & ROTH 




Shandon CitadelTM 1000 Thermo Fisher Scientific, Walldorf, 
Germany 
Walter bath WBT 222 Medingen, Dresden, 
Germany 




Thermomixer R Eppendorf, Hamburg, 
Germany 
Incubator Wärmeschrank Memmert, Germany 
 
4.2 Chemicals 
The chemical and reagents used for the development of this doctoral thesis are listed 
alphabetically in table 4. 
Table 4 List of chemicals and reagents employed for this study 
Chemicals/Reagents Distributor 
Ethylendiamintetraessigsaure (EDTA) Merck, Darmstadt, Germany 
Natriumhydroxid (NaOH) Merck, Darmstadt, Germany 
PBS w/o Ca2+ and Mg2+ PAA, Pasching, Osterreich 
Tris-buffer saline(10x) Sigma-Aldrich, Steinheim, Germany 
Tween-20 Sigma-Aldrich, Steinheim, Germany 
H2O，steril Ampuwa, Fresenius Kabi, Germany 
Formaldehydlosung 37% Merck, Darmstadt, Germany 
0.01M sodium citrate buffer, PH6.0 Sigma-Aldrich, Steinheim, Germany 
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4.3 Antibodies and probes for histology 
The antibodies and probes used for skin pathological staining and immunohistochemistry 
for the development of this doctoral thesis are listed below (Table 5). 
Table 5 List of antibodies and probes employed for the study 
Antigen Isotype Clone Dilution Distributor 
H4R Rabbit IgG NLS3775 1:90 Novus Biologicals 
Germany 
H1R Rabbit IgG LS-A1167 1:90 Lifespan Biosciences 
Germany 





































Dako, United States 
 
4.4 Patient samples and data acquisition 
Data were collected from March 2017 until April 2018 at the Department of Dermatology 
and Allergy, Charité – Universitätsmedizin , Berlin, Germany. In total, 13 healthy 
volunteers and 13 patients with a history of CholU were recruited. The presence of CholU 
was confirmed in the patients using PCE provocation testing 38. The study was approved 
by the Ethics Committee of Charité-Universitatsmedizin, Berlin, Germany (approval 
#EA1/242/15) and was registered with the German Clinical Trials Register (DRKS-ID: 
DRKS00012755). It was conducted in accordance with the Declaration of Helsinki, the 
International Conference on Harmonization (ICH), Good Clinical Practice (GCP) 
Guidelines, national laws and regulations, and wih the Standard Operating Procedures 
(SOPs) of the Department of Dermatology and Allergy, Charite - Univer-sitätsmedizin, 
Berlin, Germany. All participants gave signed informed consent at the beginning of the 
study. 
 
4.5 Clinical characterization of the patients 
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In total, 13 patients with CholU and 13 healthy controls participated in this study. One 
participant in the healthy control group did not complete the study for personal reasons. 
Overall, there were 12 women (4 women in the CholU group, 8 women in the healthy 
group), and 13 men (9 men in the CholU group, 4 men in the healthy group) participating 
in the study. None of the women were pregnant or lactating. None of the participants had 
taken corticosteroid at least 2 weeks before the provocation test. Patients were advised 
not to take antihistamines at least 3 days before provocation. Nevertheless, 4 patients 
had taken 1 antihistamine tablet within the last 3 days of provocation. No participants had 
taken corticosteroids or other MC stabilizers within the past two weeks. All participants, 
expect one healthy control, who terminated the study before the provocation, could be 
provoked. None of the participants were allergic to iodine. 
As seen in the following table, the healthy control group and the CholU group were 
comparable regarding sex, age and body mass index. There were no significant 
differences between the two groups (Table 6).  
Table 6 Participant demographics and results summary. 
Parameter Healthy controls Patients with CholU  
Number 12 13 
Sex (m/f) 8/4 9/4 * 
Age (years) 35.6 (22 - 59) 34(19 - 53) * 
Body mass index (kg/m2) 24.9 (21.1 - 34.7) 24.5 (18.5 - 31) * 
Data are presented as median with range. 
* P > 0.05 no difference between healthy control group and CholU group. 
 
4.6 Measurements 
Thirteen healthy controls and 13 patients with CholU were assessed for atopic skin 
diathesis (atopic predisposition) by using of the Erlangen Atopy Score 79. Both groups 
were assessed for disease severity via the Visual Analogue Scale (VAS), Likert scale and 
Cholinergic Urticaria Severity Index (CholUSI) 38 (Table 7) and disease activity 
(CholUAS7) (Table 8), quality of life impairment (Dermatology Life Quality Index [DLQI]) 
(Table 9) 80, Cholinergic Urticaria Quality of Life Questionnaire (CholU-QoL)(Table 10) 81], 
urticaria control test (Table12), seasonal exacerbation, global score 7, total and specific 
serum IgE, and comorbidities. 
4.6.1 Assessment of disease severity 
We validated the diagnosis of CholU and determined disease severity using a PCE 
challenge test. That is, all the patients performed a static bicycle ride for 30 minutes in a 
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pulse-controlled manner. Patients were instructed to speed up or slow down their 
pedaling so that the pulse rate eventually reached 160 beats per minute. The time of 
initiation of treatment was recorded as a sign of the severity of the disease. Observations 
continued during the 10 minutes recovery period after the 30 minutes of exercise. 
The CholU Severity Index (CholUSI) was used to assess CholU severity 38. The CholUSI 
is a sum score that takes into account the frequency of CholU symptoms (< once a month 
= 0 point; once a month = 1 point; > once a month = 2 points; once a week = 3 points; > 
once a week = 4 points; daily = 5 points; > daily = 6 points), eliciting factors (one point 
each for: physical exercise, hot bath, hot shower, emotional stress, hot food, sauna, other), 
duration of skin lesions (< 5 min = 0 point; 5 – 10 mins = 1 point; 10–20 mins = 2 points; 
20–30 mins = 3 points; 30–60 mins = 4 points; < 1 hour = 5 points) and itch (none = 0 
point; mild = 1 point; moderate = 2 points; severe = 3 points). Accordingly, the CholUSI 
score ranges from 0 to 21 points: < 5 points: very mild CholU; 5–9 points: mild CholU; 
10–15 points: moderate CholU; > 15 points: severe CholU. 
Table 7 CholUSI (Cholinergic Urticaria Severity Index) 
Frequency: Less than once a month = 0, Once a month = 1, More than once a month, 
less than once a week = 2, Once a week = 3, More than once a week = 4, Every day 
= 5, Several times a day = 6 
Trigger: exercise / effort = 1, Hot baths = 1, Hot showers = 1, Emotional stress = 1, 
Spicy food = 1, Sauna = 1, Other = 1 
Duration of skin symptoms: Less than 5 minutes = 0, 5-10 minutes = 1, 10-20 
minutes = 2, 20-30 minutes = 3, 30-60 minutes = 4, More than an hour = 5 
(Clinics for dermatology, venereology and allergy Consultation hours for urticaria, angioedema 
and mastocytosis by Prof. Dr. med. M. Maurer. ) 
VAS and Likert scale: 
Evaluation of patients with urticaria of current illness situation in the past 2 weeks: 
VAS: in the following, please assess how severe your urticaria symptoms (your disease 
activity) have been over the past 2 weeks. For this, we ask you to mark on the line 
recorded below in the most suitable place for you. The very left end of the line indicates 
that you did not have any urticaria symptoms. A cross on the right side of the line means 
that you had maximum conceivable urticaria symptoms. A cross in the middle would mean 
a moderate level of complaints. 
 
No urticarial complaints                                  Maximum imaginable urticaria complaints  
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Please rate below how much your overall quality of life has been affected by your urticaria 
over the past 2 weeks.  
 
No restriction                                             maximum conceivable restriction 
in your quality of life                                            in your quality of life 
Likert scale: in addition, we request that patients make the same documentation for their 
urticaria complaints in the past 2 weeks with the following options: 
No (complaints) Mild  Moderate Severe 
In addition, we would ask patients to make the same assessment of their quality of life in 
the last 2 weeks with the following possible answers: 
No (restriction) Mild  Moderate  Severe 
4.6.2 Assessment of disease activity  
Urticaria is assessed with urticaria activity score (UAS). The UAS measures two 
symptoms – number of wheals and intensity of itching – each on a 0 - 3 scale each day. 
The UAS was recorded by each patient daily and was obtained from the patients weekly. 
For both the number of wheals and the severity of itch, on a given day for every of the 
day in of a given week to get the weekly UAS. The possible weekly aggregate UAS ranged 
from 0 to 42. Score-based health states were defined as follows: urticaria-free = 0; well 
controlled urticaria = 1 - 6; mild = 7 - 15; moderate = 16 - 27; and severe urticaria = 28 
- 42. 
Table 8 CholUAS: Urticaria Activity Score 
Wheals Pruritus Score 
None None 0 
Mild (< 20 wheals / 
24hours) 
Mild (present but not annoying or 
troublesome) 
1 
Moderate(20 - 50 wheals/ 
24 hours) 
Troublesome but does not interfere with 
sleep 
2 
Intense(> 50 wheals/ 24 
hours or large confluent 
areas of wheals) 
Severe pruritus, which is sufficiently 
troublesome to interfere with normal dairy 
activity or sleep 
3 
 
Cholinergic urticaria is assessed with CholUAS. In daily diaries, in order to better assess disease 
activity, we require patients to record their signs and symptoms of CholU and triggering factors 
on the last 7 days before provocation. Specifically, patients recorded a pruritus intensity (itch day: 
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no = 0, mild = 1, moderate = 2, severe = 3) and their treatment intensity (weal day: no = 0, mild = 
1, moderate = 2, severe = 3) intensity of excitation (intensity of elicitor day: no exposure to inducer 
= 4, exposure to mild elicitor = 3, exposure to moderate elicitor = 2, exposure to strong elicitor = 
1). CholUAS7 is calculated as the sum of 7 days of [(weal day + itch day) x elicitor day strength], 
reaching a maximum of 168 points. A comparison of different composite scores has identified this 
score as the best score for determining the activity of CholU disease. 
4.6.3 Quality of life instruments 
Quality of life was assessed using the DLQI questionnaire and the Chronic Urticaria 
Quality of life questionnaire, following recent recommendations 80. The DLQI measures 
skin health-related quality of life, has a recall period of 7 days, consists of 10 questions 
and has a score that can range from 0 to 30, with 0 - 1 points: no impairment, 2 - 5 
points: low impairment, 6 - 10 points: moderate impairment, 11 - 20 points: severe 
impairment and > 20 points: extreme impairment. The aim of this questionnaire is to 
measure how much your skin problem has affected your life over the past week.   
Table 9 DLQI 
Item No. Over the last week 
1 Over the past week, how itchy, sore, painful or stinging has your skin 
been?    
2 Over the past week, how embarrassed or self-conscious have you 
been because of your skin? 
3 Over the past week, how much has your skin interfered with you going 
shopping or looking after your home or garden?   
4 Over the past week, how much has your skin influenced the clothes 
you wear?  
5 Over the past week, how much has your skin affected any social or 
leisure activities?  
6 Over the past week, how much has your skin made it difficult for you to 
do any sport? 
7 Over the past week, has your skin prevented you from working or 
studying?  
8 Over the past week, how much has your skin created problems with 
your partner or any of your close friends or relatives?  
9 Over the past week, how much has your skin caused any sexual 
difficulties? 
10 Over the past week, how much of a problem has the treatment for your 
skin been, for example by making your home messy, or by taking up 
time?  
(very much = 3, a lot = 2, a little = 1, not at all = 0) 
4.6.4 Assessment of disease-related quality of life  
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The German CholU-QoL assesses disease-related quality of life (symptoms, functional 
life, social interaction, therapy, emotions) from a 5 domain structure. It has 28 questions 
and each question is answered with a five-level Likert scale. The total CholU-QoL score 
has a range from 0 to 100, with higher scores indicating higher levels of impairment in 
quality of life.  
 
It shows the items of the German translation, in the order in which they appear on the 
questionnaire, along with an English equivalent and an abbreviated name. Each 
statement or question is scored on a 5-point scale, as explained. Items are preceded by 
the question: the five choices presented are: gar nicht, wenig, mittel-mäßig, stark, sehr 
stark (not at all, little, medium, severe, very severe).  
Table 10 CholU - QoL: Chronic Urticaria Quality of Life Questionnaire 
Item No. Statement Translation 
 Wie sehr haben Sie in den 
letzten 14 Tagen unter den 
folgenden Beschwerden Ihrer 
Nesselsucht (Urticaria) gelitten? 
How much have you suffered from 
the following symptoms of hives 
(urticaria) in the past 14 days? 
1 Quaddeln Wheals 
2 Hautrötungen Erythema 
3 Juckreiz Itching 
4 Hitzegefühl Feeling hot 
5 Müdigkeit Fatigue 
 Wie sehr waren Sie in den 
letzten 14 Tagen in den 
folgenden Bereichen des 
täglichen Lebens furch Ihre 
Nesselsucht (Urticaria) 
beeinträchtigt? 
How were you been affected by 
urticaria in the following 14 days in 
the following areas of daily life? 
6 Schule/Studium/Beruf School / Education / Occupation 
7 Freizeitgestaltung Recreation 
8 Tägliche Aktivitäten (z.B. 
Haushalt / Einkaufen / 
Gartenarbeit) 
Daily activities (e.g., household / 
shopping / gardening) 
9 Körperliche Aktivitäten / Sport Physical activities / sports 
10 Aktivitäten mit anderen 
Menschen 
Activities with other people 
11 Wahl der Kleidung Choice of clothes 
 Mit den folgenden Fragen 
möchten wir näher auf 
Schwierigkeiten und Probleme 
eingehen,die mit Ihrer 
Nesselsucht (Urticaria) in den 
letzten 14 Tagen verbunden 
waren: 
With the following questions, we 
would like to elaborate on the 
difficulties and problems associated 
with your hives (urticaria) in the past 
14 days: 
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12 Fühlten Sie sich wegen Ihrer 
Nesselsucht in Ihrer 
Leistungsfähigkeit 
eingeschränkt? 
Did you feel limited in your 
performance because of your 
hives? 
13 Waren sie wegen Ihrer 
Nesselsucht beeinträchtigt, 
anstrengende Tätigkeiten zu 
verrichten? 
Was your ability to perform difficult 
work impaired? 
14 Hat es Ihnen Ihre Nesselsucht 
erschwert aktiv zu sein? 
Does your urticaria make it difficult 
for you to be active? 
15 Haben Sie wegen Ihrer 
Nesselsucht Situationen oder 
Tätigkeiten gemieden, in denen 
Sie ins Schwitzen kommen? 
Have you avoided situations or 
activities that make you sweat 
because of your hives? 
16 Waren Sie wegen Ihrer 
Nesselsucht in Ihrer Mobilität 
eingeschränkt? 
Were you restricted in your mobility 
because of your hives? 
17 Haben Sie unter der 
Sichtbarkeit Ihrer Nesselsucht 
gelitten? 
Have you suffered from the visibility 
of your hives? 
18 Hat die Nesselsucht Ihnen 
Wunsch eingeschränkt, mit 
anderen Menschen zusammen 
zu sein? 
Has hives limited your desire to be 
with other people? 
19 Haben Sie wegen Ihrer 
Nesselsucht dazu geneigt 
häufiger zu Hause zu bleiben? 
Do you tend to stay home more 
often because of your hives? 
20 Haben Sie sich wegen Ihrer 
Nesselsucht in der 
Öffentlichkeit unwohl gefühlt? 
Did you feel uncomfortable with 
your urticaria in public? 
21 War Ihnen Ihre Nesselsucht 
peinlich? 
Was your urticaria embarrassing? 
22 War es Ihnen unangenehm, 
wenn andere Menschen Ihre 
Nesselsucht oder damit 
verbundenes Kratzen bemerkt 
haben? 
Did you feel uncomfortable when 
other people noticed your hives or 
the associated scratching? 
23 Haben Sie sich Sorgen 
gemacht, Ihre Nesselsucht 
könnte sich verschlimmern? 
Have you worried your hives could 
get worse? 
24 Haben Sie unter Ungewissheit 
gelitten, wann Ihre 
Nesselsuchtbeschwerden 
auftreten? 
Did the uncertainty about when the 
hives complaints would occur worry 
you? 
 Mit den folgenden Fragen 
möchten wir näher auf 
Schwierigkeiten und Probleme 
eingehen, die mit Ihrer 
Behandlung der Nesselsucht 
With the following questions we 
would like to find out more about the 
difficulties and problems associated 
with your treatment of hives 
(urticaria) in the past 14 days: 
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(Urticaria) in den letzten 14 
Tagen verbunden waren: 
25 Stellte die Behandlung Ihrer 
Nesselsucht für Sie eine 
Belastung dar? 
Did the treatment of your hives put a 
strain on you? 
26 Hatten Sie Sorge vor möglichen 
Nebenwirkungen Ihrer 
Nesslsuchtbehandlung? 
Did you worry about possible side 
effects of your hives treatment? 




Have you suffered from side effects 
of your hives treatment? 
 Fühlten Sie sich in den letzten 
14 Tagen aufgrund Ihrer 
Nesselsucht (Urticaria)...? 
Did you feel in the past 14 days due 
to your hives (Urticaria): 
28 Frustriert Frustrated? 
29 Deprimiert Depressed? 
30 Genervt Annoyed? 
 
4.6.5 Assessment of atopy 
The Erlanger criteria for the assessment of an atopic skin diathesis were developed to 
analyze, independently of the current skin disease, the atopic diathesis with respect to 
the target organ skin. Despite subjective freedom from symptoms, several of the features 
contained in the score added to skin-damaging factors.  
This score is broken down into the following 6 areas of atopy criteria: atopic family history, 
atopic self-history, atopic minimality, atopic stigmata, dermal neurovegetative, and 
laboratory values. These ranges include the features listed in Table 11. In the case of 
unclear or weak findings, only half the score can be awarded for the respective 
characteristic. 
The scoring system for this questionnaire is Category 1, no atopy (score 0-3 points); 
Category 2, atopy unlikely but cannot be excluded (score 4-9 points); Category 3, atopic 
(score 10-14 points); Category 4, clear atopic skin diathesis (score 15-19 points)，
Category 5, very strong atopic skin diathesis (score >20 points). 
Table 11 Erlanger Atopic score 
Category Characteristic 
Family medical history Eczema 
 Rhinitis / bronchial asthma 
Own medical history Rhinitis / conjunctivitis 
 Asthma allergy 
 Cradle cap 
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 Itching on uninfected skin 
 Textile intolerance 
 Metal intolerance 
 Photophobia 
Minimal forms Xerosis 
 fissures 
 Dyshidrosis 
 Pityriasis alba 
 Pulpitis sicca 
 Nipple eczema 
 Perleche 
Stigmata Palmar hyperlinearity 
 Sign of hertoghe 
 Dirty neck 
 Keratosis pilaris 
Neurovegetative  White dermographism 
 Acrocyanosis 
Laboratory values IgE > 100 U/ml 
 IgE > 200 U/ml 
 positive phadiatop(sIgE) 
For a laboratory assessment of atopy (total IgE serum level), patient serum was collected 
by venous puncture and sent to the central laboratory of the clinic (Labor Berlin Inc, Berlin, 
Germany). Total IgE was determined using the Immuno CAP System Phadia Laboratory 
Systems, Thermo Fisher Scientific Inc, Uppsala, Sweden. 
We also sent the serum to the same laboratory for assessing tryptase and Malassezia 
globosum serum level. 
 
The quantification of the total tryptase concentration with ImmunoCAP Tryptase leads to 
a risk assessment for severe allergic reactions. ImmunoCAP Tryptase measures the 
concentration of tryptase released into the serum by the MCs. MCs play a key role in 
allergic reactions and increase in number under inflammatory conditions. When activated, 
they release a variety of mediators that cause signs and symptoms of allergic reactions, 
such as B. anaphylaxis. These mediators also include tryptase and histamine. A transient 
increase in blood tryptase concentration following anaphylactic shock in a patient helps 
to determine and assess the extent of the response. A persistent elevated basal 
concentration of tryptase is an indication of a possible mastocytosis. (Serum 1.0 ml, 
MethodeImmuno-CAP fluorescence assay, reference range < 11.4 μg/l). Serum from all 
patients was analyzed for IgE against Malassezia specific IgE by the same central 
laboratory of the clinic. They calculated the results as 7 levels shown in the table below. 
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CAP class 0 < 0.35 IU/ml 
CAPclass 1 ≥ 0.35 IU/ml and < 0.70 IU/ml 
CAP class 2 ≥ 0.70 IU/ml and < 3.5 IU/ml 
CAP class 3 ≥ 3.5 IU/ml and < 17.5 IU/ml 
CAP class 4 ≥ 17.5 IU/ml and 50 IU/ml 
CAP class 5 ≥ 50 IU/ml and 99.99 IU/ml 
CAP class 6 ≥ 100 IU/ml 
 
4.6.6 Urticaria control test (UCT) 
The following questions should help patients with CholU to understand their current illness. 
For each question, we gave a score. The total score (UCT) is 16, we separated the UCT 
to two levels (UCT < 12, not controlled, UCT ≥ 12 well controlled). 
Table 12 Urticaria Control Test 
1. To what extent have you suffered from the physical complaints of the urticaria (itching, 
wheals and / or swelling) over the past 4 weeks? 
0=very severely   1= severely    2=moderately    3=mild     4=not at all 
2.  How was your quality of life affected by urticaria in the past 4 weeks? 
0=very severely   1= severely    2=moderately    3=mild     4=not at all 
3. How often has therapy for your urticaria in the past 4 weeks been insufficient to control 
your urticaria symptoms? 
0=very severely   1= severely    2=moderately    3=mild     4=not at all 
4. How well did you control your urticaria in the past 4 weeks? 
0= Not at all      1= barely     2= moderately   3= well      4= very well 
4.6.7 Seasonal exacerbation 
Patient were assessed anamnestically to defermine, whether their symptoms increased 
in summer, winter, or unchanged over the year.  
4.6.8 Global score 7  
A weekly score (global symptom score 7) was calculated as a sum of the daily scores. 
How would you rate your complaints today? 
No = 0, Mild, tolerable moderate = 1, Some restriction = 2, Very severe, severely 
noticeable, significant restriction = 3 
4.6.9 Pulse-controlled ergometry (PCE) test  
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The PCE test 38 involves a 30-min static bicycle ride at an ambient temperature of 20 – 
22.8°C. Twenty minutes acclimatization time was allowed before tests, during which time 
participants were fitted with a double sensor device attached to the forehead (double 
sensor, TDS, Draegerwerk AG, Luebeck, Germany). Starch-iodine powder (according to 
Minor’ sweat test) 82 was applied to the lower back to detect sweating. For the provocation 
test, the individual was seated on the bicycle and remained stationary until the sensors 
measured stable results for at least 1 minute. During exercise, the times of the start of 
the sweating, defined as the appearance of the first blue dots in the starch-iodine powder, 
and the start of reddening/ whealing were recorded. Physician rated the sweating grading 
by 5 levels at the end of PCE test. 
Score Sweating Starch-iodine powder 
0 Non (sweating) No change 
1 Very little Sweating only in small points or small areas  
2 Less than normal Not all areas blue 
3 Normal All blue 
4 More than normal All blue, sweat running down 
CholU patients were rated after the PCE test on their number of wheals and their itch 
severity, resulting in a UASprovo ranging from 0 to 6 points. 
a) Numbers of wheals (0 = 0; 1 to 20 wheal = 1; 20 to 50 wheal = 2; > 50 wheal = 3) 
b) Itching (none = 0, mild = 1, moderate = 2, severe = 3) 
4.6.10 Skin biopsy 
The full skin (from epidermis to fat layer) was punched before and after the PCE test. 
After the PCE test, the wheal (lesional skin) was punched in the CholU patient group. 
Normal skin (non-lesional biopsy) was punched in both CholU group before the PCE test 
and in the healthy control group (before and after the PCE test). Skin specimens were 
fixed using 4% buffered formaldehyde (Herbeta Arzneimittel, Berlin, Germany). 
4.6.11 Histology 
The embedding of the section in paraffin was carried out using the Shandon Citadel 1000 
(Waltham, USA) according to the following protocol (Table13). After embedding, 5 μm 
thick tissue sections were cut using a Microtome Finesse 325 from Shandon (Waltham, 
USA). These sections were first stained by hematoxylin-eosin staining (HE staining) 
(Table14) to visualize the nuclei and cytoplasm non-specifically.  
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Table 13 The embedding of the cuts in paraffin    Table 14 HE staining on paraffin sections 
Medium  Time of application 
(minutes) 
 Coloring Step time 
(minutes) 
 3 x xylene 10 
Aqua distilled  20  2 x absolute ethanol 5 
70% ethanol  50  2 x 96% ethanol 5 
70% ethanol  60  2 x 70% ethanol 5 
96% ethanol 50  3 x distilled water 5 
96% ethanol  60  Hematoxylin (freshly 
filtered) 
1 
Absolute ethanol  50  rinse with running water 10 
Absolute ethanol  60  Rinsing in aqua distill 1 
Absolute ethanol  60  Eosin 1 
xylene  50  Rinse 4 x in distilled 
water 
1 
xylene  60  70% ethanol 3 
paraffin  120  96% ethanol 3 
Paraffin  Unlimited  absolute alcohol 3 
   xylene 3 
   Cover with Clarion environmentally safe 
permanent mounting medium 
 
Number of MCs and in the skin-sections were assessed by the following MC specific 
stainings: 
  i) 2-Naphthalenecarboxamide, 3-(acetyloxy)-N-(2-methylphenyl)- (Naphthol AS-D) 
Chloroacetate for Specific Esterase Kit (for MC numbers) 
  ii) Toluidine blue (alternative staining for MC numbers) 
  iii) Giemsa (staining, which allows detection of MC granules). 
 
 
Table 15 AS-D staining on paraffin sections           Table 16 Toluidine blue 
Prepare AS-D solution: 1ml sodium nitrite 
solition + 1ml fast red violet LB base + 5 
ml Trizmal 6.3 buffer concentante + 1ml 






2 x xylene 5  
Coloring Step time 
(minutes) 
 2 x absolute 
ethanol 
2  
2 x xylene 10  2 x 96% ethanol 2  
2 x absolute ethanol 2  2 x 70% ethanol 2  
1 x 96% ethanol 2  Aqua distilled 5  
1 x 70% ethanol 2  0.5% Toluidine 
blue 
overnight 
2 x Aqua distilled 
(37°C) 
2  Rinsing in aqua 
distilled 
1  
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AS-D solution avoid 
light (37°C) 
15  2 x 95% alcohol 2  
1 x Aqua distilled 
(37°C) 





2  2 x xylene  
Rinse in tap water and cover with slopping 
mounting medium 
 Cover with slopping mounting 
medium 
 
Table 17 Giemsa staining on paraffin sections 
Coloring Step time (minutes) 
3 x xylene 10  
2 x absolute ethanol 5  
2 x 96% ethanol 5  
2 x 70% ethanol 5  
3 x Aqua distilled 5  
Giemsa Azur Eosin ethylene blue undiluted and filtered 1  
0.1% acetic acid 10 seconds 
Rinsing in aqua distilled 10 
3 x absolute alcohol 3 
3 x xylene 5  
Cover with Clarion environmentally safe permanent mounting medium 
Sections were analyzed using microscope of Zeiss Axioplan2, in average 5 high-power 
fields (HPF 40X) x 5 times and counting under microscope, the mean value was 
calculated. 
In-situ-hybridization 
Ribonucleic acid (RNA) histamine 1, 2, 3, 4 receptor expression staining and Tryptase-
RNA expression staining was performed with a selected number of patients and healthy 
control samples (Table 18). Histamine 1 and 4 receptors were also stained via antibody-
staining to analyze protein-expression level (Table 19). 
 
Table 18 Histamine receptors and tryptase stainings on paraffin sections (view RNA) 




3 x xylene 5 RT 
2 x absolute ethanol 5 RT 
Air dry 5 RT 
PapPen-air dry 30 RT 
Heat-Pretreatment solution 1:100 in Aqua distill 5 92°C 
2 x Aqua distill,1 x PBS 1 RT 
Protease QF 1:100 in 40°C PBS 20 40°C 
2 x PBS 1 RT 
Probe- 1:40 in prewarmed Probe-set-Diluent QT 40 hours 40°C 
3 x wash buffer* with shaking 2 RT 
Preample Mix QT  25 40°C 
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3 x wash buffer* with shaking 2 RT 
Amplifier Mix QT  15 40°C 
3 x wash buffer* with shaking 2 RT 
Label-Probe 1/6-AP 1:1000 in Label-Probe-
Diluent QF  
15 40°C 
3 x wash buffer* with shaking 3 RT 
Fast Red substrate in the dark 30 40°C 
PBS 5 RT 
Cover with slopping mounting medium 
* wash buffer: wash comp1 + wash comp2 + Aqua distilled, RT: room temperature, 
PBS:Phosphate Buffered Saline, QT: 4-acetyloxybutanoyl 4 acetyloxybutanoate, QF: methyl 
methacryla crosspolymer. 
Table 19 Histamine receptors staining on paraffin sections (antibody) 




3 x xylene 5 RT 
3 x absolute ethanol 3 RT 
2 x 95% ethanol 3 RT 
1 x 80% ethanol 3 RT 
Rinse slides in gentle running distilled water 5 RT 
Steam slides in 0.01 M sodium citrate buffer, pH6.0 20 99-100°C 
Remove from heat and let stand in buffer 20 RT 
Rinse in 1 x TBST* 1 RT 
Apply a universal protein block 20 RT 
Drain protein block from slides, apply diluted primary 
antibody 
45 RT 
Rinse slides in 1 x TBST 1 RT 
Apply a biotinylated secondary antibody appropriate for 
the primary antibody 
30 RT 
Rinse slides in 1 x TBST 1 RT 
Apply alkaline phosphatase streptavidin 30 RT 
Rinse slides in 1 x TBST 1 RT 
Apply alkaline phosphatase chromogen substrate 30 RT 
Rinse slides in distilled water 1 RT 
*TBS: Phosphate Buffered Saline             TBST: TBS with 0.05% Tween 
Photos were taken and sections were analyzed using a confocal microscope of Leica DMI 
6000 (High Performance Fortran: HPF 20X) and counting was done using Image J 
program. 
 
4.7 Statistical analyses 
Statistical analysis was done using Microsoft Excel Version 2006 and Graphpad Prism 5. 
As not all the data were normally distributed, they are all presented as median (with range) 
and mean (with standard deviation [SD]) and the statistical significance of differences 
between patient groups was calculated using Student’s t-test for independent means, as 
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this test is considered suitable for small sample sizes. Correlations were calculated using 






5.1 CholU patient characteristics  
5.1.1 Patients with CholU had a long duration of disease. 
Patients with CholU had a mean duration of their disease until presentation of 11.1 ± 10 




Fig. 3 Duration of disease in CholU patients group. 
Individual patients are shown as dots. Blank line shows mean, red whiskers represent standard 
deviation. 
  
5.1.2 Patients rated themselves as mostly moderately affected 
The majority of patients rated their disease severity (using a 3 dimensional Likert scale) 
as moderately affected (Fig. 4). Using this score, patients had in a mean of 1.9 ± 0.8 
points (range 1 to 3) in the last 2 weeks. All patients had at least one complaint.  
 
Fig. 4 Disease severity in CholU patients. 





Comparable results were seen using the VAS assessment of the same questions. 
Patients with CholU had a median level of urticaria of 4.9 ± 2.2 (range 2.3 to 9.3) (Fig. 
5A). The patient rating of VAS (disease severity) correlated with the results of the Likert 
scale. The VAS scores of the severe group were significantly higher compared to the mild 
disease group (P = 0.04) and showed a trend towards the moderate disease group (P = 
0.08). There was no significant difference between the moderate and the mild disease 




Fig. 5 VAS assessment in the CholU patient group (A) and Correlation of Likert and VAS scale 
assessment of disease severity (B).  
Individual patients are shown as dots. Black line shows mean, colored whiskers represent 
standard deviation. Asterisk marks significant differences, as calculated by t-test. 
 
5.1.3 Patients with CholU were in the mean moderately affected, using clinical 
scores 
Using newly implemented disease-specific measures, the disease severity was assessed 
by using a daily diary, as described above, documenting wheal and itch severity and 
calculating the CholU activity score 7 (CholUAS7), by implicating the elicitor on the 
respective day. Patients also rated their daily symptoms using a 3-dimensional Likert 
scale, scoring their daily symptoms form none to severe (global symptom score). A 
weekly score (global symptom score 7) was calculated as a sum of the daily scores. 
Furthermore, the CholUSI as a marker for disease severity was assessed in these 






Table 20 CholUAS7 and CholUSI in CholU patients group 
Patient characteristics Mean±SD (median; [range]) 
Duration of disease  11.1±10 (7.5; 0.8 to 29)  
Wheal 7 6.8±5.6 (5.5; 0 to 18) 
Itch 7 7.8±5.9 (7.5; 0 to 19) 
CholUAS 7*     38.2±31.7 (32；0 to 98） 
CholUSI  12.2±2.3 (11; 9 to 16) 
Global symptom score 7  6.8±5.6 (5.5; 0 to 18) 
* 7-d Sum of ([whealday + Itchday] x Intensity of elicitorday)            SD: Standard Deviation                    
CholUAS: Cholinergic Urticaria Activity        CholUSI: Cholinergic Urticaria Severity Index 
 
5.1.3.1 CholUAS7 
The established CholUAS7 correlated very well with the patients’ rating of their disease 
severity (r = 0.9, P< 0.001). The CholUAS7 was significantly higher in the severe, 




Fig. 6 CholUAS7 and correlation of CholUAS7 with VAS and global symptom score7. 
Fig. 6A CholUAS7 was positively correlated with the patients' rating of disease severity. Individual 
patients are shown as dots. Black line shows median, colored whiskers show interquartile range. 
Asterisk marks significant differences, as calculated by t-test. 
 
Furthermore, the CholUAS7 was positively correlated with the patients' VAS rating of their 
disease severity (Fig 6B), and with the patients' Likert scale of their disease severity (r = 
0.9, P < 0.001, data not shown), and with global symptom score 7 (r = 1.0, P < 0.0001, 






    
 
Fig. 6 B/C. Correlation of CholUAS7 with VAS (patient rating of disease severity) (B), and 
correlation of CholUAS7 with global symptom score7 (C). Individual patients are shown as dots. 
Black line shows the correlation. Asterisk marks significant differences as calculated by the 
Pearson test. 
 
5.1.3.2 CholUSI: most CholU patients had moderate CholU. 
In line with previous results, the majority of patients with CholU (n = 9, 69%) could be 
grouped into the moderate group using the CholUSI. Of the remaining four, two (15%) of 
them fell into the mild CholU group and the other two (15%) were in the severe CholU 
group regarding the CholUSI (Fig. 7A).  
 
The CholUSI was not significantly correlated with diseases severity (VAS) (r = 0.6, P> 
0.05) and the CholUAS7 (r = 0.4, P > 0.05), but there was a trend towards the patients' 
rating of disease severity (Likert scale) (r = 0.6, P = 0.05) and global symptom score7 (r 
= 0.5, P = 0.07). Interestingly, a longer duration of disease was significantly correlated 
with the CholUSI score (r = 0.8, P < 0.001) (Fig. 7B). 
  
 




Distribution of patients with CholU regarding their CholUSI (A) Bar graph shows patient numbers 
in each category and correlation of CholUSI with duration of disease (B) Individual patients are 
shown as dots. Black line shows the correlation. Asterisk marks significant differences as 
calculated by the Person test. 
 
5.1.4 Quality of life  
 
5.1.4.1 Patients rated themselves as mostly moderately for current disease 
situation in the past 2 weeks 
Patients rated their quality of life impairment using a 3-dimensional Likert scale in the 
mean as moderately affected (1.9 ± 0.8, range 1 to 3) within the last 2 weeks before 
presentation (Fig. 8B). Comparable results were seen in the VAS assessment of the same 
question. The CholU patient group had a median level of quality of life impairment of 5.0 
± 2.5 (range 1.3 to 8.4) (Fig.8A). 
 
 
Fig. 8 Quality of life in the CholU patient group. (A) Individual patients are shown as dots. Black 
line shows mean, colored whiskers represent the standard deviation. (B) Bar graph shows patient 
numbers in each category. 
Most patients had correlation scores between their disease severity rating and their 
quality of life impairment rating (Fig. 9). Only four patients scored in different categories 






Fig. 9 Correlation of disease severity and quality of life. 
 Bar graph shows urticaria severity and quality of life of Likert scale score in each patient.  
 
5.1.4.2 DLQI assessment showed moderate to strong impairment in most 
patients with CholU patients 
Quality of life was assessed using the DLQI questionnaire and the CholU-Qol, following 
recent recommendations80,81. The mean DLQI of the CholU patient group was12.4 ± 5.1 
(7 to 16 range). Most patients in our patient group had moderate or strong impairment. 
One patient scored extremely high, and none scored no or low impairment. (Fig. 10). 
 
 
Fig. 10 DLQI assessed quality of life in patients with CholU. 
Individual patients are shown as dots. Black line shows median, colored whiskers show 
interquartile range. Dotted line represents cut-offs between different categories (as described on 
the right side of the figure). 
 
The DLQI was highly correlated with the patients’ ratings of the quality of life (VAS and 




0.7, P = 0.02) (Fig. 11A) and also positively correlated with the Likert scale rating (r = 0.7, 
P = 0.004) (Fig. 11B). 
 
 
Fig. 11 Correlations: DLQI with VAS (A) and DLQI with the Likert scale (B). 
Individual patients are shown as dots. Black line shows the correlation. Asterisks mark significant 
differences as calculated by the Person test. 
 
5.1.4.3 CholU-Qol of patients with CholU showed that the quality of life 
impairment has a broad range 
The mean CholU-QoL score was 42 ± 12.2 in the CholU patient group, with a broad range 
of 25 to 67.5 (Fig. 10A). This disease-specific score correlated overall very well with the 
DLQI (r = 0.7, P = 0.01) (Fig. 12B). 
 
 
Fig. 12 CholU-Qol scores and correlation with DLQI. 
CholU-Qol scores of patients with CholU (A) and the correlation with DLQI in the CholU patient 
group (B). Individual patients are shown as dots. Black line shows mean, colored whiskers 
represent standard deviation. Black line shows the correlation. Asterisk marks significant 





The CholU-Qol also correlated significantly with the patients’ ratings of quality of life 
impairment using VAS (r = 0.8, P = 0.004) and the Likert scale (r = 0.6, P = 0.03) in the 
CholU patient group (Fig. 13A and B). 
 
 
Fig. 13 Correlations: CholU-Qol with VAS (A) and Likert scale (B). 
Individual patients are shown as dots. Black line shows the correlation. Asterisks mark significant 
differences as calculated by the Person test. 
5.1.5 Treatment / Antihistamines 
Patients documented their antihistamine intake in the last week before presentation. On 
average, patients took 3.9 ± 3.2 tablets per week (median 5.0; 0 to 9) (Fig. 14). Overall 
two groups of patients can be separated: patients that took antihistamines (n = 8) and 
patients who did not (n = 5). 
 
 
Fig. 14  Antihistamine intake per week of patients with CholU. 
Individual patients are shown as dots. Black line shows median, colored whiskers show the 
interquartile range. 
 
When analyzing the correlation between antihistamine intake and disease severity or 




CholUAS7 (r = 0.008, P > 0.05), DLQI (r = 0.02, P > 0.05) or CholUSI (r = 0.001, P > 0.05) 
or CholU-Qol (r = -0.01, P > 0.05). 
5.1.6 CholU, in almost all patients was not well controlled 
The urticaria controlled test was designed to understand the effect of the current 
treatment of patients (UCT < 12 urticaria not controlled, UCT ≥ 12 urticaria well 
controlled). Of the 13 patients in the CholU group, 12（92%）indicated that their disease 
was not well controlled (Fig. 15).  
 
Fig. 15  UCT score of patients with CholU. 
Individual patients are shown as dots. Black line shows mean, colored whiskers represent 
standard deviation. Dotted line represents cut-offs between different categories (as described on 
the right side of the figure). 
 
Eight patients had taken antihistamines in the last week (1-9 tablets per week) before the 
assessment; the remaining patients had no such therapy. We divided them into an 
antihistamine-treated group and a group without antihistamine therapy. We found that the 
mean UCT of the antihistamine group was comparable to the non-antihistamine group 
(P > 0.05), indicating no significant influence of this therapy in controlling the disease (Fig. 
16). 
 




The lines show median. 
 
5.1.7 Seasonal distribution of CholU aggravation showed winter was the worst 
season  
One of the theories of the pathophysiology of CholU was the theory of poral occlusion, 
which is meant to be most severe in winter. Accordingly, we asked the patients about 
their symptom severity in respect to the seasonal changes. Almost half (46%) of patients 
with CholU reported that their CholU symptoms were unchanged over the whole year, 39% 
of them had more severe symptoms in winter, and only 15% had worse symptoms in 
summer. Interestingly, in this study all (4) of the female CholU patients reported no 
seasonal changes (Fig. 17). 
 
Fig. 17  Seasonal and sex distribution of the CholU group. 
Bar graph shows patient numbers in each category.  
 
5.1.8 Provocation test 
5.1.8.1 CholU patients and healthy controls have comparable markers at the 
onset of sweating 
All CholU patients and healthy controls took the PCE test. In the healthy control group, 
the median time to onset of sweating was 17.5 min (range 13 to 25), which was 
comparable to the CholU patient group (median 16.6 min, range 11 to 22, P > 0.05) (Fig. 
18A). Also the heart rate (HR) at onset of sweating (healthy: median 122.4, range 98 to 
149) was similar (CholU: median 120.4, range 102 to 138, P > 0.05) (Fig. 18B).These 





Fig. 18  PCE threshold levels of the healthy control group and the CholU patient group. 
Individual patients are shown as dots. Black lines show mean, colored whiskers represent 
standard deviation. 
 
Using physician assessment of the sweat grading in the sweat test according to Minor, 
we saw that ten patients with CholU had very little or decreased sweating behavior and 
three patients had normal sweating. None showed above-average sweating behavior (Fig. 
19). 
 
Fig. 19  Sweat grading in the CholU patient group. 
Bar graph shows patient numbers of each category. Patients who had very little sweating were 
represented in red, less than normal in black, and normal in green. 
5.1.8.2 Patients with CholU develop wheals after the onset of sweating 
In patients with CholU, the development of skin reddening (flare reaction) (median 20.7 
minutes, range 14 to 27) and whealing (median 23.8 minutes, range 14 to 35 minutes) 
always occurred after the onset of sweating (median16.6 minutes, range 11 to 22) (Fig. 





Fig. 20 Time between sweating and skin reddening/ whealing in the CholU patient group. 
Onset of sweating is represented by red dots, onset of skin reddening by blue triangle, and onset 
of whealing by purple triangles. 
 
Patients started whealing after a mean time of 7.2 ± 4.9 minutes after the onset of 
sweating. Six (46%) patients started to wheal 4-7 minutes after onset of sweating and in 
four (31%) patients, sweat was more delayed after 8-12 minutes. Two (15%) patients had 
a very short time of two minutes between sweating and whealing and one patient had a 
very long time of 21 minutes.  
5.1.8.3 Provocation UAS score  
Patients with CholU had a mean UASprovo score of 3.9 ± 0.4 (range 1 to 6) (Fig. 21A). The 
UASprovo correlated very well with the patients’ ratings of disease severity (Likert scale). 
The group with high disease severity had significantly higher UASprovo compared with the 
mild group (P = 0.04). There was a trend towards higher UASprovo in the moderate 
compared to the severe group, but this did not reach significance (P = 0.08) (Fig. 21A). 
There was also a strong correlation with the VAS patient ratings of their disease severity 
and the UASprovo (r = 0.8, P < 0.001).  
 
When looking at the correlation of the symptoms provoked by PCE (UASprovo) and the 
daily dairy scores of the patients (CholUAS7), we saw a significant, but rather weak 





Interestingly, the UASprovo of the PCE was highly correlated with the quality of life 
measures used in these patients. Patients had high correlations with their self-rated VAS 
and Likert scale of life quality impairment (Fig.21 C/D), DLQI (Fig. 21E) and CholU-Qol 
(Fig. 21F). There were no differences in the UASprovo regarding seasonal exacerbation 
(P > 0.05) or the sex of patients (P > 0.05). 
 
 
    
 
   
   




Individual patients are shown as dots. (A) Black line shows median, colored whiskers show the 
interquartile range. Asterisks mark significant differences as calculated by the t-test. (B, C, D, E, 
F) Black line shows the correlation. Asterisks mark significant differences as calculated by the 
Person test. 
5.1.8.4. Influence of Antihistamines 
Eight (62%) patients with CholU had taken antihistamines within one week, four (31%) 
patients from the CholU group had taken antihistamines within 24 hours before 
assessment. None of the patients had taken corticosteroids of other MC stabilizers for 
the past two weeks.  
 
To analyze if the intake of antihistamines was influencing the disease severity, patients 
were divided into two groups: i) CholU patients with antihistamine intake (23%) and 
ii)CholU patients without antihistamine intake (77%) (Fig 22). Five (56%) of the patients 
who had not taken antihistamines had developed symptoms in the last 24 hours before 
provocation testing, whereas only one (25%) of patients who took antihistamines had 
symptoms, but this difference was not significant (P > 0.05) (Fig 22). There was no 
significant difference between the two patient groups regarding CholUAS7 (P > 0.05), 
CholU-Qol (P > 0.05), DLQI (P > 0.05), and CholUSI (P > 0.05). 
 
Fig. 22 Treatment with antihistamines could have an influence on disease symptoms . 
Bar graph shows patient numbers in each category. Patients who had symptoms are represented 
in red and those who did not are in blue (unpaired t-test). 
  
Interestingly, patients numbers 04, 06, 09 and 11 had taken antihistamines in the last 24 
hours before the PCE test (Fig. 20). In these patients, the mean delay of the onset of 
whealing after the start of sweating was higher compared to those who did not take 




patients who took antihistamines showed a trend towards longer delay of onset of 
symptoms compared to the patients without antihistamine (P = 0.09), possibly due to low 
patient numbers (Fig. 23).  
 
Fig. 23 Time from sweating to onset of whealing in patients who did / did not take antihistamines 
in the last 24 hours before PCE. 
Individual patients are shown as dots. Black line shows median and colored whiskers show the 
interquartile range. 
 
Patients with or without antihistamine intake were not different regarding their onset of 
sweating (P > 0.05) or onset of whealing (P > 0.05). 
 
5.2 Investigation of possible MC triggers 
As whealing is the key feature of CholU, MCs are thought to play a key role in the 
pathophysiology of the disease, we investigated possible clinical MC triggers in patients 
with CholU.  
5.2.1 Atopic predisposition is frequent in patients with CholU   
Using the Erlangen atopy score, the mean atopy score was significantly higher (P = 0.001) 
in the CholU group (7.9 ± 3.0) compared to the healthy control group (3.7 ± 2.3) (Fig. 
24A). Separating the patients and healthy controls into the proposed five categories, 
seven of the 12 controls (58%) were found to have no atopy (category 1), the remaining 
five healthy controls (42%) fell into category 2 (atopy unlikely but cannot be excluded), 
and no one was found to be atopic or severely atopic. In the CholU group, one patient 
(8%) was found to have no atopy (category 1), eight (62%) fell into “atopy unlikely but 







Fig. 24 Patients with CholU have a higher mean Erlangen atopy score (A) and atopy is more 
frequent in the CholU group than in the healthy control group (B).  
(mean and standard deviation, t-test) (A) Individual patients are shown as dots. Blank line shows 
mean and colored whiskers represent standard deviation. (B) Bar graph shows patient numbers 
in each category. Erlangen atopy scores are divided into: Category 1, no atopy (Score 0 – 3 
points); Category 2, atopy unlikely but cannot be excluded (score 4 – 9 points); Category 3, atopic 
(score 10 – 14 points); Category 4 clear atopic skin diathesis (score 15 – 19 points), Category 5 
very strong atopic skin diathesis (score > 20 points). 
 
5.2.2 Total IgE and specific IgE 
The mean total IgE serum levels in the CholU patient group (190.2 ± 207.9) was higher 
than in the healthy control group (137.3 ± 237.5), but this difference was not significant 
(P > 0.05) (Fig. 25). 
  
Seven (54%) patients with CholU had elevated total serum IgE levels (> 100 kU/mL) and 
in five (38%) of them, the total serum IgE was > 200 kU/mL. In comparison, in the healthy 
control group only two (17%) participants, displayed a total IgE of over 100 kU/mL. There 






Fig. 25 The total IgE levels of the two groups. 
Individual patients are shown as dots. Black line shows median and colored whiskers show the 
interquartile range.  
 
5.2.3 Malassezia-specific IgE may be a marker for more severe and more 
prolonged disease 
As IgE directed against a subform of Malassezia (Malassezia globosa) had been 
described as a relevant pathogenetic mechanism in CholU patients, we assessed 
Malassezia-specific IgE in both patients with CholU and healthy controls (Fig. 26). Three 
out of 13 patients had detectable levels of IgE anti Malassezia, but only one patient had 
values above the cut off of 0.35 IU/ml.  
 
Fig. 26 Two groups of Malassezia spp-specific IgE distribution. 
Individual patients are shown as stars in the healthy control group and dots in the CholU patient 
group. Black line shows the median. Dotted line represent cut-offs between different categories 
(as described on the right side of the figure). 
 




Combined with other clinical data, we found that the increase in Malassezia-specific IgE 
was associated with a longer duration of illness (Fig. 27), but not with the severity of the 
disease (CholUAS7, P = 0.3; CholUSI, P = 0.4). And there was no correlation between 
Malassezia-specific (Malassezia spp.) IgE and CholU-Qol (r = 0.06, P = 0.5)/ DLQI (r = 
0.2, P = 0.2)/ Provocation UAS (r = 0.04, P = 0.5)/ VAS (r = 0.1, P = 0.3)/ CholUAS7 (r = 
0.3, P = 0.1)/ CholUSI (r = 0.2, P = 0.2). 
 
Fig. 27 Malassezia with duration and severity of CholU. 
Individual patients are shown as dots. Black line shows the median and, colored whiskers show 
the interquartile range.  
 
 
5.3 MC numbers and features 
Here, we investigated if MCs in the skin have different features in patients with CholU 
compared to healthy controls. 
5.3.1 MC numbers: Histological findings in patients with CholU compared to 
healthy controls  
5.3.1.1 Absolute number of MCs 
To further elucidate the role of MCs in the pathophysiology of CholU, we analyzed the 
number of MCs in the skin of both healthy controls and patients with CholU. To assess 
MC numbers, we compared naphthol AS-D chloroacetate for Specific Esterase Kit (AS-
D staining) and toluidine blue staining in skin biopsies of unaffected skin before 
provocation (Fig. 29). There were significantly higher absolute numbers of MCs in the 






Fig. 28 Different staining of MCs between two groups before provocation. 
Bar graph shows mean numbers in each group and whiskers show the standard deviation. Control 
group is represented in blue and the CholU group is in red (Control group n = 12, CholU group n 
= 13). 
 
When analyzing the MC distribution in the dermal layers of the skin sections, we saw that 
MC numbers were significantly increased throughout all dermal layers, with the biggest 
and most significant differences in the uppermost layer and in the deeper layers (Table 
21). 
 
Table 21 MCs in the layers before provocation 
Cells / 400 x HPF Control  CholU  P value 
Layer 1 4.4±2.2 6.1±2.3 0.03 * 
Layer 2 3.2±1.8 3.8±2.9 0.08 
Layer 3 1.6±1.1 2.6±2.5 0.003 ** 
Layer 4 1.2±1.0 1.8±1.1 0.1 
Layer 5 0.7±0.9 1.6±1.8 0.03 * 
               





     Healthy control                            CholU patient 





Fig. 29 Examples of AS-D / toluidine blue stainings in skin biopsies before provocation. 
Examples of AS-D / toluidine blue stainings in skin biopsies of unaffected skin before provocation 
in a healthy control and in a CholU patient (from a single patients in each group), the biopsies in 
both of these two patients were non-lesional skin (pictures shown at 200X magnification).  
 
Regarding MC distribution, we did not see differences between patients with CholU and 
healthy controls. MCs were often localized near vessels, subcutaneous glands and 
nerves, but also dispersed in the tissue. 
 
MC number in lesional skin of CholU patients are slightly elevated compared to 
non-lesional skin 
When we performed the provocation test, we also took biopsies from whealing skin in 
patients with CholU and from comparable skin regions of healthy controls (no skin 




same skin samples of wheals in patients with CholU (lesional) and skin samples of healthy 
controls after provocation (non-lesion), we saw comparable results as seen in the skin 
before provocation. There were significantly higher numbers of MCs in patients with 
CholU compared to healthy controls (Fig. 30, P = 0.02). As before, we examined the MC 
distribution in the dermal layers of two groups (Table 22). The lesional skin after 
provocation showed higher numbers of MCs in all dermal layers compared to non-lesional 
skin in healthy controls after provocation with highly significant. 
 
 
Fig. 30 Different staining of MCs between the two groups after provocation. 
Bar graph shows mean numbers in each group and whiskers show the standard deviation. Control 
group is represented in blue and the CholU group is in red (Control group n = 12, CholU group n 
= 13). 
 
Table 22 Number of MCs in the skin layers after provocation (mean, SD) 
cells/ 400x HPF Control  CholU  P value 
Layer 1 4.4±1.7 7.3±3.3 0.001 *** 
Layer 2 3.1±2.0 5.5±2.5 0.007 ** 
Layer 3 1.7±0.9 2.9±1.4 0.007 ** 
Layer 4 1.2±1.0 2±1.0 0.007 ** 
Layer 5 0.6±1.0 1±0.8       0.01 * 






Healthy control                       CholU patient 
（non-lesional skin, after provocation）   （lesional skin, after provocation） 
      
  
Fig. 31 Examples of AS-D / toluidine blue stainings in skin biopsies after provocation 
Examples of AS-D / toluidine blue stainings in skin biopsies of unaffected and affected skin after 
provocation in a healthy control and in a patient with CholU. The biopsies in the healthy control 
group were non-lesional and in the CholU group they were lesional (pictures shown at 200X 
magnification). 
 
Differences in MC numbers in the skin before and after provocation 
We compared the MC number between the control group and CholU group before and 
after provocation. We found that the number of MCs in the healthy control group was 
comparable before and after provocation, whereas in the CholU group, there was a 
tendency towards even higher MC numbers in lesional (whealing) skin after provocation 








Fig. 32 MC numbers in the skin before and after provocation 
The average of absolute MC numbers of two stainings +/- SD (A) and The number of MCs 
between the two groups before and after provocation (B) and the MC numbers of the CholU 
patient group before and after group (C).  
 
5.3.1.2 Correlation with clinical data 
MC numbers in the skin (in the affected skin after provocation) did not correlate with 
clinical features, such as CholUAS7 (r = -0.2, P = 0.5), onset of sweating (r = 0.03, P = 
0.9), provocation UAS (r = 0.3, P = 0.4), DLQI (r = -0.2, P = 0.4) and CholU-Qol (r = 0.02, 
P = 0.3). 
 
Interestingly, MC numbers were also not correlated with total serum IgE (r = 0.06, P = 
0.8) or IgE against Malassezia spp. (r = -0.02, P = 0.9) or Erlangen Atopy score r = -0.02, 





5.3.2 MC degranulation upon provocation 
We aimed to assess the degranulation status of MCs before and after provocation. We 
found that there was MC degranulation in both the control group and in the CholU patient 
group before and after provocation (Fig. 33). No clearly visible differences in the 
degranulation status were visible. 
             
Healthy control                               CholU patient 
Non-lesional skin, before PCE              Non-lesional skin, before PCE 
              
            Healthy control                         CholU patient 
Non-lesion, after PCE               Non-lesional skin, after PCE 
  
Fig. 33 Examples of Giemsa staining in skin biopsies 
Examples of Giemsa staining in skin biopsies of unaffected and affected skin before and after 
provocation in a healthy control and in a patient with CholU. The biopsies in the healthy control 
group were non-lesional, in the CholU group before provocation, they were non-lesional and in 
the CholU group after provocation they were lesional (pictures shown at 400X magnification). 
  




Degranulation of MCs lead to release of histamine, leukotrienes, cytokines, chemokines 
and neutral proteases (chymase and tryptase). Histamine, prostaglandins and 
leukotrienes are not stable in serum and therefore difficult to measure. In contrast, 
tryptase is relatively stable in serum after centrifugation and was chosen as a MC 
degranulation marker in this study. 
5.4.1 There was no significant difference in tryptase between CholU patients 
and healthy control subjects. 
To analyze MC activation, we compared the tryptase between the healthy control group 
and the CholU patient group before and after provocation. The mean values in the CholU 
patient group before provocation (4.9 ± 2.3 kU/l) were slightly higher compared with the 
healthy group (4.5 ± 1.8 kU/l), but all of them were within the normal range. There was no 
significant difference between the two groups in the mean value of tryptase (P > 0.05). in 
the healthy group, there was no change in the average value before (4.5 ± 1.8 kU/;) and 
after (4.5 ± 1.8 kU/l) provocation  (Fig. 34A) or in the CholU patient group (Fig. 27B), 
before (4.9 ± 2.3 kU/l) and after (4.8 ± 2.0 kU/l, P > 0.05) provocation. Among them, eight 
patients had slightly lower trypatse values after provocation, one patient had missing 
information of the pre-provocation value, and the values of the remaining patients were 
minimally higher than before provocation (Fig. 34B). 
 
 
Fig. 34 The distribution of tryptase before and after provocation 
The tryptase of before provocation is presented in blue circles and after provocation in red 
squares. Black lines connect the tryptase before and after provocation. 
5.4.2 Changes in Mast cell mediator-related receptor expression 
As histamine is the major MC mediator resulting in skin reddening, whealing and itching, 




symptoms in the patients with CholU. MCs generate and release histamine upon 
activation. Histamine exerts its action via specific receptors (H1-H4 receptors) on various 
cells, inducing vessel dilation, itch promotion and regulatory mechanisms on MCs. We 
wished to see if the expression of the histamine receptors is differently (regulated) in 
patients with CholU compared to healthy controls.  
 
5.4.2.1 Histamine receptor expression in skin: higher expression and 
upregulation of H4 receptors in patients with CholU 
Using RNA-hybridization we stained for H1 to H4 receptor expression in skin samples 
(Fig. 38). Unaffected skin of both healthy controls and patients with CholU expresses low 
levels of H1 and H2 receptors. H3 receptor was not detectable in any skin sample. In 
almost all the participants, H4 receptor RNA expression was detectable (see Fig. 35). 
The H4R expression was significantly higher in patients with CholU compared to healthy 
controls (P = 0.02) (n = 7). 
 
Fig. 35 Histamine receptors before provocation of the healthy control group and the CholU patient 
group. 
 
In lesional skin of patients with CholU, after provocation, H4R expression was even higher, 
whereas exercise provocation alone in healthy controls did not upregulate H4R 
expression. In contrast, there was a higher number of H4R positive cells in lesional skin 






Fig. 36 Histamine receptors before provocation of the healthy control group and the CholU patient 
group 
 
To compare histamine receptors expression with MC numbers, we stained for tryptase 
RNA in these skin samples and saw, as described above, higher expression in CholU 
patient skin and even higher expression in lesional skin after provocation (Fig. 37). We 
compared the H4 receptor and tryptase between the healthy control group and the CholU 
patient group before and after provocation. There was no distinct difference before and 
after provocation in healthy control group (P > 0.05) (n = 5).   
 
Fig. 37 The positive cells of H4R and tryptase between two groups before and after provocation 
 
Overall, there were more H4R-positive cells than trpytase-positive cells. This difference 
was even more pronounced in patients with CholU compared to healthy controls. There 
was no significant difference between the number of tryptase-positive and H4R-positive 





              Before provocation                  After provocation 
              Non-lesional skin                    Lesional skin   
 
 
         




     
 
Fig. 38 Examples of histamine and tryptase stainings in skin biopsies 
Examples of histamine and tryptase stainings in skin biopsies of unaffected and affected skin 
before and after provocation in the healthy control and the CholU patient group. (pictures shown 
at 400X magnification). CholU skin sections were stained for the different histamine receptor 
subtypes (red) (shown in A, B, E, F, G, H) and for the mast cell marker tryptase (red) (shown in I, 
J). Note that only few cells stained positive for H1R and H2R, the H3R staining was absent in 
cutaneous tissue. Due to the limited number of stainings, no statistical analysis had been 
performed. 
 
5.4.2.2 Acetylcholine esterase expression 
Aberrations in the AchE expression has been proposed as an underlying 
pathomechanism, therefore we were interested in the different expressions of this in 
healthy contols and patients with CholU. We specifically looked for AchE in the eccrine 
gland epithelial cells to see if there were differences in the non-lesional skin of patients 
with CholU before provocation and in the lesional skin after provocation. 
In first staining of our patients and three healthy controls, we saw a decreased expression 




one patient who also had less sweating behavior upon PCE. Due to the limited number 
of staining, no statistical analysis had been performed.  
Healthy control                       CholU patient 
Non-lesional skin, before provocation   Non-lesional skin, before provocation 
      
             Healthy control                       CholU patient  
Non-lesional skin, after provocation      Lesional skin, after provocation 
       
Fig. 39 Examples of AchE staining of sweat glands in skin biopsies 
Examples of AchE staining of sweat glands in skin biopsies of unaffected and affected skin before 
and after provocation in healthy controls and in patients with CholU. (pictures shown at 200X 






6.  Discussion 
In this study, which included 13 patients with CholU from a specialized tertiary clinical 
urticaria center and matching healthy controls, we aimed to explore the role and relevance 
of MCs in the pathophysiology of patients with CholU c. To address this aim, patients 
were clinically characterized and histological samples of the skin before and after 
provocation testing were analyzed for MC numbers, MC activating factors, MC products 
and MC product related dysregulations. 
 
6.1 Clinical data of patients with CholU 
In our study, the CholU patient group comprised of four females and nine men, who had 
a mean age of 34 years. In 1994, Zuberbier et al. reported that  the prevalence of CholU 
in women (12%) was slightly higher than that of men (10%) 52. In our case, we recruited 
more male patients in our study. Whether men are more affected or are more likely to 
seek medical help and participate in clinical research remains unclear. 
CholU is often regarded among physicians as "a young man's disease" 52, but recent 
publications also show patients with late onset of disease 63. The average age in our 
patient group was 34 years, with a broad range from 19 to 53 years. However, most of 
the older patients had a long duration of CholU. On average, the duration of CholU was 
11.1 years (SD = 10 years), with a range from 0.8 to 29 years, meaning most patients 
had an onset of disease at a young age. 
 
Patients with CholU were mostly moderately affected by their disease 
In our study, we analyzed patients who were mostly moderately affected, as rated by the 
patients and by using clinical scores. In this project, patients with CholU rated their 
disease severity globally with VAS, the Likert scale and global symptom score 7, and 
documented their symptoms in disease specific scores (CholUSI, CholUAS7). These 
disease-specific scores showed good correlation with the global severity measures, 
which corroborates the severity of disease. Only one of the 13 patients with CholU 
included in this study, rated herself as well-controlled, maybe because she had a long 
duration of disease (27 years) and she had adapted to the symptoms and learned how to 
control her condition in daily life.  




Patients with CholU had a long duration of disease of up to 29 years (mean 11.1 years), 
which was much longer than in another report, where it was 48 months 61. In the latter 
report, the authors stated that this short duration could be due to loss of follow up of the 
patients. 
 
In our study, patients with long disease duration scored higher in CholUSI, which 
implicates the amount of trigger factors, frequency of symptoms and symptom duration, 
but was not connected with other clinical scores. CholUSI was introduced in a recent 
paper 74, but it has not been validated so far. The relevance of this score is not yet clear, 
but this correlation indicates that long-lasting disease is also associated with a higher 
disease burden. 
 
Quality of life impairment parallels disease severity in CholU 
For the quality of life impairment, the mean DLQI in our study among all patients was 12.4, 
which was consistent with previous reports of mean DLQI scores in CholU (mean DLQI 
11.8 in 30 patients with CholU 74.The mean DLQI scores for psoriasis was reported as 
9.7 83, and for CSU it was around 10.9 84, indicating that in our study, patients with CholU 
experienced an even higher level of impairment of their quality of life, then the average 
patient with psoriasis or CSU.  
 
Furthermore, in this study, a newly introduced disease-specific quality of life instrument, 
CholU-Qol, was used for the quality of life assessment 81. This score ranges from 0 to 
100 and patients in this study showed a mean value of 42. This score was well correlated 
with the DLQI and patients’ global ratings (VAS and Likert scale). The CholU-Qol has not 
yet been validated in lager studies, but it may serve as a valuable tool for clinical trials 
and improve routine patient management. 
 
Antihistamine intake had little influence on disease severity and disease control 
In this study, almost all the patients with CholU took one antihistamine tablet per day on 
a regular basis, but were advised to stop treatment for one week before the PCE test, 
and especially in the 24 hours before the PCE test. In order to avoid drug interference 
with clinical outcomes, we advised patients to try not to take antihistamines, MC stabilizes 




CholU took antihistamines in the last week before assessment and four of them took 
antihistamines in the last 24 hours before the PCE test.  
 
Most of the patients with CholU who had taken one antihistamine tablet per day rated 
themselves as not having well-controlled symptoms. Currently, effective therapeutic 
approaches for the treatment of CholU are not well established. In a previous publication, 
there was only one clinical trial published that evaluated cetirizine as a treatment for 
CholU in 24 patients 85, it reported that taking cetirizine (10 mg or 20 mg) for three weeks 
was successful for the treatment of patients with CholU. Koch et al. reported that 
antihistamine updosing reduces disease activity in patients with difficult to treat CholU 74. 
Antihistamines are the first line therapy in CholU 40. Antihistamines have been shown to 
be effective in CholU treatment 85,86. However, Koch reported that even higher 
antihistamine doses did not completely inhibit CholU symptom development. In the study, 
we saw that antihistamine intake did not correlate/influence clinical scores like CholUAS7, 
CholU-Qol, DLQI or CholUSI and that antihistamines did not improve the UCT score, 
indicating no major influence on the disease control. In out study with limited patient 
numbers, we only saw an influence on the delay of onset of symptoms upon sweating. 
CholU patients that had taken AH had a more delayed onset of the symptoms, but this 
difference just missed significance (P = 0.09). It was consistent with previous reports that 
antihistamine updosing delayed onset of the symtoms, but it is not significance 74.  
 
Males, but not females, reported seasonal changes in CholU 
Half of the patients with CholU rated their symptoms as unchanged over the whole year. 
Differences in seasonal deterioration have been reported in Japanese patients with more 
severe disease activity during winter season. CholU was in winter 56,87. In our study, 46% 
of patients with CholU complained about CholU throughout the year, with the rest being 
more severe in winter than in summer. This is consistent with previous reports 56,78,87. 
However, an Indian study of patients with CholU showed a moderate prevalence in 
October and November 54. This may be because in India, October and November are hot 
and humid. In Germany this could be explained by the fact that, Europe does not have 
hot and humid weather throughout the year. The types of stimuli that elicit for CholU are 
climbing steps, sweating, walking, sports, mental stress, hot and spicy food, and alcohol. 




potently due to sweat gland blockage or acetylcholine/acetylcholine receptor 
abnormalities 55,88. 
 
Upon provocation, patients with CholU had comparable onset of sweating, but 
probably a reduced amount of sweating 
To objectively analyze the occurrence and severity of symptoms, a provocation test has 
been used for decades 35,64. In our case, all the participants performed a static bicycle 
ride for 30 minutes using PCE 38. Patients were instructed to speed up or slow down their 
pedaling so that the pulse rate increased three times per minute and to eventually reach 
160 beats per minute. We compared the PCE threshold levels (onset of sweating time, 
increase in HR at sweating onset, increase in bpm at onset of sweating, and the time to 
the first discoloration of the iodine starch test according to Minor’s sweat test from these 
two groups). There was no significant difference, indicating that patients with CholU do 
not have a dysfunction in the initiation of sweating.  
 
Less sweating has been reported in previous publications 89. We suspected that patients 
with CholU could have a sweat allergy. Thus, patients with CholU with acquired 
generalized hypohidrosis and with a sweat allergy may be classified as two distinct 
disease entities based on different pathogeneses.  
 
Patients with CholU develop wheals after onset of sweating. However, there were no skin 
changes or wheals in the healthy control group. Interestingly, in the CholU patient group, 
the onset of wheals appeared after the onset of sweating and marked the beginning of 
skin changes. Thus, we hypothesized that patients with CholU may have a 
hypersensitivity to their own sweat. Previous reports have indicated that sweat is an 
exacerbating factor in atopic dermatitis (AD) 90–92 and that a sweat allergy exists in 
patients with CholU. This result was consistent with the results of sweat hypersensitivity, 
proven by positive ASwST (autoperspiration sweat skin test) and basophil histamine 
release test published by Jung in 2015 93. 
 
Pulse-controlled exercise provocation testing is both highly sensitive and specific for 
diagnosing CholU 38. Wheals were produced in all patients with CholU but not in healthy 
controls. Additionally, it is the first protocol that allows assessment of disease severity, 




correlation between the symptoms provoked by PCE and the daily diary scores of the 
patients (CholUAS7), was a significant, but rather weak connection with disease severity.  
 
With the provocation UAS, we detected a positive correlation with disease-specific quality 
of life impairment (CholU-Qol) and a weaker correlation with DLQI. This confirms that 
PCE is a valid and valuable instrument for the diagnostic workup of patients with CholU, 
for confirming the diagnosis and assessing trigger thresholds. PCE also does both. 
  
In our study, there was no significant difference in the onset of sweating upon PCE 
provocation, indicating that patients with CholU did not have problems with the onset of 
sweating, but most patients showed reduced rate of sweating in the test. Most the patients 
showed a decreased sweating behavior in the sweat test. This feature of CholU patients 
had been described by Sawada 89,94. 
 
Symptoms upon provocation occur after sweating and are correlated with disease 
severity, quality of life impairment, CholU7, DLQI and CholU-Qol scores 
Antihistamines could have an influence on the delay of whealing. Four patients with CholU 
had taken antihistamines in the last 24 hours before provocation. The mean delay of onset 
of whealing after the onset of sweating was higher in patients who had taken 
antihistamines compared to those who had not taken antihistamines in the last 24 hours. 
The difference is not significant, but trended towards this result, possibly due to the low 
patient numbers. 
 
6.2 MC triggers  
 
Atopic predisposition is frequent in CholU 
Our study showed that patients with moderate to severe CholU showed high rates of 
atopy. In 1987, Hischmann et al. reported a high prevalence of atopy (34%) in patients 
with CholU 44. Using the Erlangen Atopy score, 31% of our patient population was atopic 
and none of healthy control group were atopic. Using the Erlangen Atopy score, the 
previously reported higher scale value, perhaps due to an overall increase in atopic 
response due to a different assessment of specificity 95,96, or because we chose patients 




reported an atopic patients population of 57% in a selected cohort, possibly due to the 
selected patient population of rather severely affected patients 97. Atopy is associated 
with female sex, which is consistent with the recent German cohort study 96. 
 
Patients with CholU exhibit elevated total IgE serum levels 
Previous reports have shown that the total IgE levels are elevated in patients with chronic 
spontaneous urticaria 98 and in patients with CholU 97. Atopic predisposition is thought to 
be associated with elevated total serum IgE levels, but there are few reports to prove this. 
Furthermore, no correlation of seasonal exacerbation and total or specific IgE levels have 
been seen in previous studies 56,87.  
Thirteen patients with CholU (54%) had elevated total serum IgE levels, that is, > 100 
kU/ml and in 38% of them the total IgE was > 200 kU/ml. However, in the healthy control 
group, 17% had total IgE levels > 100 kU/ml. Surprisingly, it was not only the CholU 
patient group but also the healthy control group that had high and comparable total serum 
IgE levels. There are several theories to explain this. Firstly, the increased total IgE levels 
may indicate that participants with or without CholU are in general ‘allergy prone’. The 
test for this was originally designed for atopic skin diseases, it may not be detected by 
the Erlangen Atopic score. Secondly, elevated total IgE may be a sign of extrinsic 
reactivity to environmental allergies (classical atopy). However, it is also possible that 
autoantigens are the hallmark of the intrinsic reactivity of ‘self-allergies’. This concept has 
also been proposed for CSU in which IgE has been detected 99–101. 
According to previous reports, the higher total IgE was a marker for more severe allergic 
disease (e.g. acute AD and eczema) in any age 102,103. 
 
Malassezia-specific IgE can be detected in selected patients with CholU 
Malassezia-specific IgE is the a specific IgE that positively correlates to moderate to 
severe AD but this is controversial, because the clinical significance of this finding is 
unclear 91,104. It has been reported that Malasszia acts as a major histamine-releasing 
antigen in human sweat allergy. Moreover, serum levels of Malasszia-specific IgE in 
patients with AD and CholU were significantly higher than those in normal controls 90. 
Currently, almost all published papers came from Japan. To our knowledge, no report in 
caucasion patients regarding this specific IgE had been published so far. To address the 
question, if our patient cohort also exhibit IgE against Malassezia, we measured the levels 




group to compare the levels. As a result, in the CholU patient group, there was one 
participant who had a significant increase of specific IgE and two participants who had 
detectable levels of specific IgE. None from the healthy control group had detectable 
specific IgE levels to Malassezia. Combined with other clinical data, we found that the 
increase in Malassezia specific IgE in CholU patients was associated with a longer 
duration of disease, but most likely, this is due to the limited number of patients. This 
association did not reach significance (P = 0.06). No correlation with disease severity or 
quality of life markers could be seen, but again, the numbers of patients are very low and 
no final meaningful conclusions can be made here.  
 
Despite the detection of specific IgE to Malassezia, this does not necessarily indicate the 
necessity of an antimycotic therapy 105. Nevertheless, desenitisation therapy using 
autologous sweat or Malassezia globosa peptides has been shown to be beneficial for 
patients with intractable CholU due to sweat allergy 90.   
 
6.3 MC numbers 
The main goal of this study was to explore the role and relevance of MCs in patients with 
CholU. CholU is an edema of the skin, and molecules released by MCs cause blood 
vessels to dilate and fluids to penetrate the skin. MCs play an important role in most 
patterns of CholU, and release histamine and other inflammatory mediators. We analyzed 
the difference in MC numbers and degranulation status between the CholU patient group 
and the healthy control group. We then compared the variations in MC numbers and in 
degranulation status after motion stimulation between the two groups. 
 
MC numbers are elevated in the skin of patients with CholU  
We found that there were significantly higher absolute numbers of MCs in the skin of 
patients with CholU compared to healthy controls. MCs were found at all levels of the 
dermis, where they are grouped and often localized near vessels, subcutaneous glands 
and nerves, or dispersed in the tissue. There was no significant difference regarding this 
aspect between patients with CholU and healthy controls.  
 
In 1950, the measurement of MC numbers in the skin at different sites of the body was 




individuals were found to be between 44 and 50 MCs/mm2 107–109. The normal range for 
the forearm was between 31.5 and 62.4 MCs/mm2 108,110.  
 
In our study, there was no significant difference before and after provocation in healthy 
persons, and the MC numbers of healthy controls were between 20 and 60 MCs/mm2. In 
the healthy controls MC numbers had a greater variation, maybe because the biopsies 
were taken from different parts of body (our skin biopsies were from the upper arm, upper 
leg or abdomen). We found that the MC numbers in the upper leg were higher than those 
of the upper arm (mean 45 MCs/mm2) and the MC numbers of the upper arm (mean 38 
MCs/mm2) were higher than those of the abdomen (20 MCs/mm2). These results were 
consistent with previous reports that human cutaneous MC populations are different 
depending on the region of the body as shown by MC mapping studies of the whole body 
107,111.  
 
In the CholU patients group, MC numbers in non-lesional skin before provocation showed 
significantly higher numbers of MC, compared to HC. Numbers of MC were almost 
doubled, compared to HC, but the population density of the MCs before provocation (non-
lesional skin) were still within the normal range 107,111.  
 
In CholU patients, there was a tendency towards even higher MC numbers in the site of 
lesional skin (after provocation) of the patients, but this difference was not significant. 
Also, most of the lesional skin biopsies were within the normal range, but all of them were 
in the high range of over 50 MCs/mm2. Eleven (85%) were even close to the upper limit 
of 66.4 112. Two of the CholU patient samples were a little higher than the normal range. 
 
In the literature, very little data about MC in the skin of CholU patients are available. In 
one case report of a patient with combined CholU and symptomatic dermographism, 
population density of MCs in pre-challenged skin and after provocation wheals were 
within the normal range, but also showed increased numbers of MCs post-challenge 112. 
In the past, there was no systematic statistical analysis of the difference numbers of MCs 
in CholU between before and after provocation. 
 
MCs were counted independently in several separate skin layers and we discovered that 




the subcutis, which consistently contained the lowest numbers of MCs. This was 
consistent with previous reports 111, which analyzed different layers in healthy human 
skin. In our study we saw no significant differences of the MC distribution from the 
superficial skin layers to the deeper skin layers in the skin from patients with CholU before 
and after provocation. Of special notice, there was a significant difference in each skin 
layer between healthy individuals and patients with CholU, always with higher numbers 
in ChoU patient skin. In further studies, we need to clarify if skin MC levels of CholU 
patients are linked to disease activity and if skin MC numbers decrease in response to 
effective or spontaneous remission of CholU. 
 
6.4 MC products 
Degranulation detection of mast cells upon exercise challenge failed 
We aimed to compare the degranulation status of MCs before and after provocation. 
However, we could not find any visible differences in both the control group and the CholU 
group before and after provocation. This is different from previous reports 113 which they 
show that MC degranulation in the area of wheals has been demonstrated repeatedly by 
light and electron microscopy. This failure of detection of MC degranulation could be due 
to technical limitations of the Giemsa staining, the previous reports used molecular 
immunopathology methods. 
 
In the serum of allergic patients MC degranulation e.g. in anaphylactic situations can be 
monitored by measurement of tryptase 114–116. Tryptase is a serine protease that is 
primarily produced and stored in MCs. Changes of less than 1ng/ml are considered 
normal, increases of 1-15 ng/ml as non-specific or anaphylactoid, and changes of more 
than 15ng/ml as true anaphylactic reactions 117,118.  
 
In our study, we compared serum tryptase levels between the healthy control group and 
the CholU patient group before and after provocation. There was no significant difference 
in tryptase levels between these two groups. Only two of our participants had small 
changes of more than 1ng/ml. None of them had changes of more than 2ng/ml. However, 
in other forms of urticaria, despite severe skin involvement significant raise in tryptase 
levels had been detected 119, probably because of the patients with CholU were in the 





Histamine receptor and Acethylcholine Esterase expression 
 
H4R is upregulated in the skin of patients with CholU compared to healthy control 
skin 
 
MCs generate and release histamine during anaphylactic reactions, and there is 
pharmacological evidence that histamine regulates this process via specific receptors. 
Histamine is multifunctional and ubiquitously released from tissues of MCs and blood 
basophils 12 and exerts its effect through activation of four histamine receptors (H1-H4). 
In human skin H1 and H2 receptors have been convincingly demonstrated to be 
expressed 120–122. There is little or no evidence of expression of H3 receptors in human 
skin and was only shown to be present in human brain tissue12. The histamine H4 
receptor is the newest member of this histamine receptor family, and is expressed 
throughout the gastrointestinal tract as well as in the liver, pancreas and bile ducts 123. 
Recently, evidence of H4 receptors in human skin has also been reported 12. 
 
Non-sedating H1 antihistamines and sgAHs are recommended as the first line treatment 
of mild to moderate chronic urticaria 72, but in the clinic, many patients do not respond to 
standard non-sedating H1 antihistamine doses 40,56. Accordingly, the question is, if other 
histamine receptors are involved in the pathophysiology of the disease to provide new 
insights into the mechanisms controlling self- and paracrine-induced histamine-induced 
MC function.  
  
As for the other histamine receptors, H1 and H2 receptors only exist in few cells in our 
biopsies, while H3 receptors could not be detected in our slides. This is consistent with a 
previously reported paper on human skin MC, where expression of H2 and H4, but not of 
H3 receptors had been shown 12. However, in our study there was only a very weak 
expression of H1/H2 receptor. It is unclearly if this is similar in other forms of urticaria, as 
no reports in the literature found to confirm this.  
 
According to our fluorescence imaging results, the cells stained with the H4 RNA probe 
are consistently high in the human skin tissues of both the CholU patient group and the 





In our RNA and immunohistochemistry (IHC) results, cells expressing H4 were more 
frequently detected than cells stained with tryptase, indicating that H4 receptor is 
expressed in cells other than MCs. In a report of Lippert et al., double stainings, co-
localizating tryptase and H4 receptors only accounted for a few cells of all stained cells, 
also indicating that the majority of H4 expressing cells in allergic patients are not mast 
cells 12.  
 
We found that there were positive H4R cells in vascular structures of the skin, but in mice, 
it has been reported that H4 receptors are not involved in vascular responses 27. 
Obviously, many of these conclusions were made before the discovery of H4R, and 
therefore, should be reconsidered.  
 
In summary, the high number of H4 receptor expressing cells is consistent with previous 
reports in other allergic diseases, but their functional significance, especially in CholU, is 
still unclear. 
 
Acethycholine esterase (AchE) expression is downregulated in the skin of patients 
with CholU compared to healthy control skin 
Both direct and indirect theories in the interaction of Ach with MCs have been proposed 
in the sweating-associated histamine release from MCs 124. The mechanisms underlying 
CholU remain unclear, as several controversial findings have been reported 124. Ach had 
been shown to induce degranulation in rat MCs 125,126. Acethylcholine is a very small 
molecule with short half life in the tissue. Acordingly Acethylcholine cannot be consistenly 
stained in histology 127.  
 
Since acetylcholine is known to induce both sweating and wheals when injected 
intradermally, it has been considered that the cholinergic stimulus can elicit wheals as 
seen in CholU 128–130. AchE is a degrading enzyme of acetylcholine, and changes in the 
AChE expression might contribute to the pathogenesis of CholU131. It was demonstrated 
by a binding assay that muscarinic cholinergic receptors and AchE are reduced in the 
skin of patients with CholU as compared with the healthy controls 132. 
 
In our study we also found a decreased expression of AchE in some CholU skin samples 




patient who had almost no AchE expression also had less sweating in the PCE test, which 
is in line with Japanese publications about CholU with hypohidrosis or anhidrosis were 
decreased expression of AchE. Here, especially for the CholU patients with anhidrosis, 
almost no AchE expression has been shown 131. 
 
Upon provocation, the AchE expression increased significantly in some CholU patients, 
but the significance of this finding is unclear. Also, AchE stainings had not been performed 
in all samples, and the limited number of patients and controls does not allow for 




1. Patients with CholU in our cohort had a long duration of disease and rated 
themselves as mostly moderately affected. Most patients with CholU had an onset of 
disease at a young age. Most of our patients with CholU reported moderate to strong 
impairment and almost all patients with CholU did not have a well-controlled disease 
status. Antihistamine intake had little influence on disease severity and symptoms. 
Interestingly, most patients reported seasonal aggravation of the symptoms in winter.  
 
2. PCE testing is highly sensitive and specific for diagnosing CholU. Upon PCE, 
onset of sweating was comparable in patients with CholU and healthy persons. The 
PCE test showed that patients with CholU did not have a problem with the onset of 
sweating, but most of the patients with CholU had very little or decreased sweating 
behavior. Patients with CholU always developed wheals after the onset of sweating. The 
symptoms upon provocation (UASprovo) were correlated with disease severity and quality 
of life impairment. 
 
3. Atopic predisposition is frequent in patients with CholU. Patients with CholU 
showed higher rates of atopic stigmata compared to healthy persons, and patients with 
CholU exhibited an elevated total IgE serum level. Specific IgE against the skin resident 
fungi Malassezia may be a marker for a more prolonged courses of disease. 
 
4. Mast cell numbers are elevated in the skin of patients with CholU. Our results 




controls, but we failed to detect degranulation of MCs upon exercise challenge. Further 
studies are needed to clarify if skin MC levels of CholU patients are linked to disease 
activity and if skin MC numbers decrease in response to effective or spontaneous 
remission of CholU. 
 
5. The MC mediator tryptase did not increase in the serum upon provocation in 
CholU patients. There was no significant difference between patients with CholU and 
healthy persons in the serum before and after provocation. Tryptase expressing mRNA, 
resembling MCs, could be detected in both CholU patients and healthy controls. . 
6. Human skin expresses H1, H2, H4 receptors, but not H3 receptors. In the analyzed 
skin samples, we detected few H1R and H2R at mRNA expression levels, H3R-specific 
mRNA was undetectable. Surprisingly, highest expression was seen for H4R mRNA 
levels. In the future, we would like to investigate whether these histamine receptors 
contribute to the pathophysiology of the disease. 
 
7. Decreased expression of Acetylcholine esterase in CholU. Sweat glands of CholU 
patients showed decreased expression compared to sweat glands of healthy persons, 
and was associated in one case with reduced sweating behaviour. For meaningful 
conclusions, stainings in a larger number of patients and correlation with clinical features 
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